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Abstract 
Pulmonary arterial hypertension (PAH) is an often fatal disorder resulting from several 
causes including heterogeneous genetic defects. While mutations in the bone morphogenetic 
protein receptor type II (BMPR2) gene are the single most common causal factor for 
hereditary cases, pathogenic mutations have been observed in approximately 25% of 
idiopathic PAH patients without a prior family history of disease. Additional defects of the 
transforming growth factor beta (TGF-β) pathway have been implicated in disease 
pathogenesis. Specifically, studies have confirmed activin A receptor type II-like 1 
(ACVRL1), endoglin (ENG) and members of the SMAD family as contributing to PAH both 
with and without associated clinical phenotypes. Most recently, next-generation sequencing 
has identified novel, rare genetic variation implicated in the PAH disease spectrum. Of 
importance, several identified genetic factors converge on related pathways and provide 
significant insight into the development, maintenance and pathogenetic transformation of the 
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pulmonary vascular bed. Together, these analyses represent the largest comprehensive 
compilation of BMPR2 and associated genetic risk factors for PAH, comprising known and 
novel variation. Additionally, with the inclusion of an allelic series of locus-specific variation 
in BMPR2, these data provide a key resource in data interpretation and development of 
contemporary therapeutic and diagnostic tools. 
 
Key Words: BMPR2; ACVRL1; ENG; SMAD1; SMAD4; SMAD9; CAV1; KCNA5; 
KCNK3; EIF2AK4; haploinsufficiency; locus heterogeneity 
 
Introduction 
Heritable pulmonary arterial hypertension (HPAH) (PPH1; MIM# 178600) is a severe, 
progressive autosomal dominant vascular disorder, predominantly affecting the arterial 
circulation and, in particular, the pulmonary arterioles [Tuder et al., 2013]. Histopathological 
investigation reveals abnormal muscularization of these structures, which leads to a chronic 
elevation of pulmonary arterial pressure, often resulting in right heart failure 2-3 years post-
diagnosis in the absence of the contemporary treatment protocols [Vonk-Noordegraaf et al., 
2013]. Identification of mutations in the BMPR2 gene in probands with a family history of 
disease provided the first insight into the molecular pathogenesis of HPAH [Deng et al., 
2000; Lane et al., 2000]. Subsequently, BMPR2 mutations were identified in a cohort of 
idiopathic patients (IPAH) [Thomson et al., 2000]. Since, causal variation has been described 
in nine additional genes, in cases that include PAH associated with other conditions (APAH). 
Here, we describe molecular genetic analyses of the 10 functionally characterized genes that 
cause PAH (Figure 1) and provide a compilation of all mutations identified to date. The 
continuing identification of genetic factors, as explored in this report, provides unique insight 
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to the genetic mechanisms driving disorders of pulmonary vascular function. Furthermore, 
these studies offer the foundation for the discovery and delivery of novel therapeutic options. 
 
Key Components of the BMP Signaling Pathway 
The BMPR2 gene (MIM# 600799) encodes a type II receptor of the TGF-β family of 
signaling molecules. The mature polypeptide is composed of a signal peptide (encoded by 
exon 1), an extracellular domain (exons 2-3), a single transmembrane domain (exons 4-5), a 
highly conserved eukaryotic protein kinase region (exons 6-11) and an unusually large 
cytoplasmic tail (exons 12-13) amongst TGF-β receptors species [Liu et al., 1995]. In the 
canonical pathway, BMPR-II binds ligand in a heteromeric complex with a type I receptor, 
which may be activin receptor-like kinase 1 (ALK1), -2 (ALK2), -3 (ALK3/BMPR1A) or -6 
(ALK6/BMPR1B), to initiate activation of intracellular partners within a cell-specific context 
[David et al., 2009; Rigueur et al., 2015]. Phosphorylation of the receptor SMAD proteins (R-
SMADs) 1, 5 and 8 leads to their association with the nuclear chaperone SMAD4. This 
signaling complex translocates to the nucleus, where it acts in combination with 
transcriptional co-activators and -repressors to effect control of target gene expression 
(Figure 1). BMPR-II signaling has been established as essential to a multitude of fundamental 
cellular processes including proliferation, apoptosis, differentiation and migration [Shi and 
Massague, 2003]. 
 
Mutations of BMPR2 Predispose to the Majority of Hereditary and Idiopathic Forms of 
PAH  
Herein, we describe an additional 370 independent variants of BMPR2 in patients either 
previously excluded from or ascertained since the last comprehensive mutation update in 
2009 [Machado et al., 2009]. Of these, 108 were identified as part of this study and were 
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generated by specialist PAH centers based in Germany, France, North America and the UK 
(Table 1, Table 2). The research was prospectively reviewed and approved by a duly 
constituted ethics committee for each center. Probands were assessed for point mutations and 
large gene abnormalities using multiple screening technologies including Southern blotting, 
denaturing high-performance liquid chromatography, multiplex ligation-dependent probe 
amplification (MLPA), dye-terminator and next-generation sequencing (NGS). All variants 
considered to be pathogenic were absent from a control population of at least 200 
chromosomes and public variation databases including dbSNP v142 
(http://www.ncbi.nlm.nih.gov/SNP) and the 1000 genomes project 
(http://www.1000genomes.org) and/or have been previously demonstrated to have a 
functional impact. For a current estimation of population frequencies, we have additionally 
checked all point mutations reported here against the Broad Institute Exome Aggregation 
Consortium (ExAC) database v0.3 (http://exac.broadinstitute.org), comprising over 60,000 
exomes derived from independent sequencing projects. Mutation nomenclature employs 
parameters set by the Human Genome Variation Society (http://www.hgvs.org/mutnomen). 
Taken together with previous reports [Machado et al., 2006; 2009], these data provide 
evidence of a total of 668 germline variants underlying PAH, thereby consolidating BMPR2 
as the major causal gene for familial cases and subjects previously classified as IPAH. The 
spectrum and range of BMPR2 defects in this study comprise the major mutation categories 
which, in general, correlate with existing data [Machado et al., 2006; 2009]. Namely, we 
record missense variants leading to amino acid substitution (n=86, 23%), nonsense mutations 
(n=107, 29%), frameshift defects resulting from small insertions/deletions (n=79, 21%) and 
splice-site variation (n=33, 9%). However, and by contrast to earlier studies, we identified a 
significantly higher prevalence of major gene rearrangements (n=61, 16%) and single 
nucleotide mutations in the 5-prime untranslated region (5′ UTR) (Table 1, Table 2, Supp. 
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Table S1). This, most likely, is a consequence of screening centers expanding the analysis of 
gene re-arrangements to include all exons of BMPR2, combined with a growing recognition 
that mutation short-fall within cohorts is potentially explained by defects harbored within 
non-coding regions of BMPR2 [Machado et al., 2006]. For example, we report a total of four 
recurrent 5′ UTR mutations resulting from a guanine to adenine change (c.−669G>A) likely 
to abolish specificity for an SP3 transcription factor binding site [Wang et al., 2009]. In 
combination, these genetic findings reinforce haploinsufficiency as the molecular mechanism 
for this disease [Machado et al., 2001; 2006; 2009]. Moreover, this report provides a 
comprehensive compilation of distinct variants (n=384) across the BMPR2 locus since the 
first identification of the gene (Supp. Table S2). A combination of genetic and functional 
studies have firmly established a large proportion of these to be likely pathogenic while 
others, although compelling, remain to be fully elucidated as disease-causing. These data 
have now been made available in the ClinVar database 
(http://www.ncbi.nlm.nih.gov/clinvar). 
 
Distribution and Biological Significance of BMPR2 Variation 
Although variation has been described across the entire coding structure of the gene, the 
mutation load differs significantly across exons, indicating both the likely existence of 
mutation hot-spots and potential regions of key functional importance. Taken together with 
previously reported findings, our analyses indicate that the majority of amino acid 
substitutions cluster in exons encoding the ligand-binding domain and key catalytic regions 
of the kinase domain, namely exons 2-3, 6-9 and 11 respectively. By contrast, exons 1, 4, 10 
and 13, encoding receptor regions of uncertain importance to function, have a low frequency 
of missense mutation (Figure 2A). However, assessment of individual nucleotide defects 
within the BMPR2 open reading frame, relative to exon length, illustrates variant load by 
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exon may be resultant on an abnormally high frequency of recurrence (e.g. exon 12) which 
corresponds to a low percentage of affected bases (Figure 2B). Conversely, exon 9 whilst 
harboring a relatively modest 6.7% of all reported coding variants, contains the highest 
proportion of independent nucleotide defects (n=30) relative to exon size (148 bp). In 
combination with previous reports, the majority of mutations predict incorporation of a 
premature termination codon in the mRNA (n=483, 72%) and, as previous functional studies 
have demonstrated, result in degradation of the message through the nonsense-mediated 
decay pathway [Aldred et al., 2007; Nasim et al., 2008]. 
Cysteine substitutions comprise the majority of missense mutations in the extracellular 
ligand-binding domain and are concentrated on 9 of 10 conserved residues, which are 
essential for the formation of five disulfide bridges necessary to maintain the integrity of this 
highly ordered three-dimensional structure (Figure 3) [Greenwald et al., 1999]. Moreover, 
this analysis has indicated the existence of additional critical residues. Notably, mutation of 
an asparagine (p.N126S), adjacent to the frequently mutated cysteine residue (p.C123R, 
p.C123S), is observed on seven independent occasions [Machado et al., 2009] (Table 1, 
Supp. Table S1), highlighting its putative significance to extracellular domain function. The 
majority of tested mutations in the kinase domain of BMPR-II abolish catalytic function as 
determined by in vitro BMP/SMAD luciferase reporter gene assays. By contrast, the 
significance of mutations within the cytoplasmic tail remains enigmatic, as these receptors 
retain significant capacity for downstream signaling through the SMAD family. Yet, these 
defects appear to perturb non-canonical pathways which include signaling through the 
cytoskeleton-associated factors LIMK-1 and Tctex-1 [Foletta et al., 2003; Machado et al., 
2003]. In addition, studies have suggested that missense variants present across all the 
functional domains of BMPR-II trigger constitutive up-regulation of p38MAPK indicating a 
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perturbation of one or more SMAD-independent pathways yet to be fully investigated 
[Nishihara et al., 2002; Rudarakanchana et al., 2002]. 
 
Clinical Significance 
Extracellular Domain Mutation Spectrum 
Transient over-expression and subcellular localization of constructs harboring cysteine 
substitutions, specifically p.C60Y, p.C117Y, p.C118Y, p.C123R and p.C123S, have 
previously shown intracellular retention of these receptor species combined with a dramatic 
diminution of SMAD activation [Rudarakanchana et al., 2002]. Here, we report further 
cysteine substitutions likely to underlie structural variation in BMPR-II (p.C34R, p.C60G/R, 
p.C66G/R/Y, p.C84F/G/R, p.C94G/R, p.C99F/R/Y, p.C117R/S, p.C118W) (Figure 3). 
Utilization of these genetic observations with combinatorial functional studies facilitated an 
exploration of receptor rescue and restoration of signaling. By targeting the p.C118W mutant 
receptor with chemical chaperones, namely thapsigargin, glycerol or sodium 4-
phenylbutyrate, a demonstrable and significant increase in plasma membrane localization of 
receptor species was observed concomitant with enhanced phosphorylation of SMADs 1 and 
5. Rescued trafficking also led to an increase in the density of wild-type BMPR-II at the cell 
surface [Sobolewski et al., 2008]. This study provides an arresting example of how 
exploitation of genetic insights may lead to the potential development of future targeted 
therapeutic options in PAH. 
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Variants of Unknown Significance 
Analyses of amino acid substitutions by PolyPhen, PROVEAN and SIFT bioinformatic 
tools [Kumar et al., 2009; Adzhubei et al., 2013; Choi and Chan, 2015] lead to ambiguous 
conclusions of pathogenicity in a proportion of observed missense variants reported herein. In 
the present dataset, a total of 13 variants are predicted by at least two algorithms to be non-
damaging and/or benign (Table 2). In order to achieve greater confidence in assigning 
pathogenic status, it is important to assess such in silico predictions in the context of genomic 
data derived from substantive populations, for example the ExAC database. Comparison of 
missense variants against this combined cohort identified five variants with a population 
allele frequency greater than 0.000015, based on the most conservative measure of PAH 
prevalence in the literature (15 cases per million) [Archer et al., 2010]. Of interest, the two 
most commonly observed variants (p.V348I and p.Y589C) had been previously determined 
as damaging by at least two prediction methods and, therefore, had not been classified as 
variants of unknown significance (VUS). In the remaining three cases, the population data 
supported the in silico predictions which, taken together, provide further evidence for unclear 
pathogenicity (Table 2). One additional variant (p.T766A), previously designated VUS status 
by prediction algorithms, was present in the ExAC database but with a population allele 
frequency lower than our assigned threshold. Through these combined analytical techniques, 
we have identified a total of 15 variants that might be considered of uncertain significance 
from a genetic perspective (Table 2). While employing such analytical tools is of emerging 
value in mutation data interpretation, these analyses demonstrate that they must be treated 
with caution as: 1) the two approaches utilized may produce conflicting outputs, leading to 
ambiguity in interpretation; 2) large cohort datasets may contain study participants for whom 
the phenotype cannot be definitively assigned. Further, variants with a low population allele 
frequency in an apparently normal cohort may also be explained by the reduced penetrance of 
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this condition. Together, this highlights a continuing role for functional studies, as a gold 
standard, to determine the true impact of observed variation in BMPR2, which is of value to 
both diagnostic and basic science understanding of the physiological role of this receptor. In 
addition, these observations indicate the likely existence of as yet unexplored pathways 
underlying pathogenesis.  
 
 
Uncommon TGF-β Family Variation in PAH 
Mutations of Receptor Species and Functional Outcomes 
PAH infrequently clinically co-presents with the autosomal dominant vascular disorder 
hereditary hemorrhagic telangiectasia (HHT), characterized by the presence of 
mucocutaneous telangiectasia and visceral arteriovenous malformations. PAH-associated 
HHT is caused by molecular defects in ACVRL1, encoding a type I receptor of the TGF-β 
family, and to a lesser extent by mutations of the ENG gene which encodes a type III, or 
accessory receptor (Figure 1). In rare instances, ACVRL1 mutations have been identified in 
PAH patients without HHT but typically in early-onset disease thereby not precluding the 
development of the latter condition in later life [Harrison et al., 2003; Fujiwara et al., 2008]. 
Here we have compiled complete data on 66 mutations for both genes (ACVRL1, n=57; ENG, 
n=9), including 61 previously reported variants and 5 novel mutations underlying the 
development of PAH with and without HHT (Table 3). In ACVRL1, the majority of this 
variation occurs within the vital kinase domain of the protein (exons 6-10) resulting in 
pathogenic amino acid substitutions (n=42, 74%) in marked contrast to the BMPR2 pattern of 
predominantly truncating mutations and, indeed, the mutation spectrum in HHT alone. A 
recent study conducted in a cohort of 43 IPAH patients identified two missense variants in 
BMPR1B (p.S160N and p.F392L). However, contrary to previous reports, these variants 
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induced SMAD9 signaling with concomitant induction of transcriptional activity [Chida et 
al., 2012a]. These studies suggest that further functional investigations are required for 
clarification of the pathogenic impact of these variants. 
 
Mutations within Intracellular Partners of the BMP Signaling Pathway 
Conventional functional candidate gene strategies conducted in Asian and European 
patient panels have subsequently identified independent mutations in the BMP-specific 
SMAD pathway, namely SMAD1 (n=1), SMAD4 (n=2) and SMAD9 (n=3) [Shintani et al., 
2009; Drake et al., 2011; Nasim et al., 2011] (Table 3). Of these, the SMAD1 and -4 defects 
have been described as VUS due to in vitro luciferase SMAD responsive elements reporter 
assays demonstrating an unclear impact on the canonical pathways [Nasim et al., 2011]. 
However, these analyses did not investigate SMAD-independent pathways, implicated in 
disease pathogenesis, leaving open the possibility that the identified variants may 
deleteriously affect other BMP related systems. By contrast, SMAD9 mutations (PPH2; 
MIM# 615342) lead to a marked reduction of SMAD transcriptional activity and a down-
regulation of the BMP target gene Id1 [Shintani et al., 2009; Nasim et al., 2011]. Of interest, 
heterozygous SMAD9 mutations have been observed to perturb non-canonical downstream 
pathways, in particular, micro-RNA (miRNA) processing. Examination of a human patient 
with a SMAD9 nonsense mutation (p.R294*) indicated a modest reduction of Id1 expression 
in contrast to a complete abrogation of miR-21. In vitro restoration of miR-21 by over-
expression led to a reversal of the hyperproliferative mutation-positive phenotype. These data 
suggest a specific role for SMAD8 in PAH pathogenesis and SMAD4-independent signaling 
[Drake et al., 2011]. 
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Genotype-Phenotype Correlation in Risk Alleles of the BMP Pathway  
In 53-86% of patients with familial aggregation and 14-35% of IPAH patients mutations in 
the BMPR2 gene have been identified [Sztrymf et al., 2008; Girerd et al., 2010a; Pfarr et al., 
2011; Liu et al., 2012; Kabata et al., 2013]. Patients who carry BMPR2 mutations differ in 
several important aspects from IPAH patients who are BMPR2-negative [Soubrier et al., 
2013]. Investigators have reported that HPAH patients with pathogenic variants in BMPR2 
develop this disorder at a younger age (38.53 ± 12.38 vs. 45.78 ± 11.32 years, p <0.001) 
[Girerd et al., 2010b; Pfarr et al., 2011], and have a more severe clinical and hemodynamic 
phenotype at diagnosis [Koehler et al., 2004; Sztrymf et al., 2008; Austin et al., 2009a; Pfarr 
et al., 2011]. BMPR2 mutation carriers undergo diagnostic catheterization almost 10 years 
earlier than patients with no identified BMPR2 defect. Furthermore, compared with BMPR2-
negative IPAH patients, BMPR2-positive patients have a higher pulmonary vascular 
resistance measured at diagnostic catheterization, are less likely to demonstrate acute 
vasoreactivity [Elliott et al., 2006; Rosenzweig et al., 2008], and are more likely to progress 
to death or lung transplantation [Sztrymf et al., 2008]. These observations all suggest that 
BMPR2 mutations lead to a more severe PAH phenotype. Of note, patients with missense 
variants present with a higher degree of morbidity and mortality than those with truncating 
defects, suggestive of a more severe impact on the signaling pathway [Austin et al., 2009b]. 
However, BMPR2 mutations are not associated with a worse exercise capacity and prognosis. 
The younger age of BMPR2 mutation carriers may explain the similar survival and exercise 
capacity despite worse hemodynamics as compared with BMPR2-negative patients. Most 
recently, Girerd et al. indicated that BMPR2 mutation position may influence clinical 
phenotype. Specifically, PAH patients with a point mutation within the cytoplasmic tail of 
BMPR2 displayed a later age of onset, lower pulmonary vascular resistance and, of note, a 
higher proportion of acute vasodilator response by contrast to patients harboring mutations 
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outside of this domain. In addition, in vitro assays suggested that cytoplasmic domain 
mutations tolerated activation of the Smad pathway, which is indicative of a lower degree of 
penetrance [Girerd et al., 2015]. 
These findings appear not to be influenced by gender [Girerd et al., 2010b]. However, 
there is a trend for more severe prognosis of the disease in males, particularly in male 
BMPR2 mutation carriers. This observation is consistent with the observation that PAH 
mortality is most closely associated with male gender [Humbert et al., 2010]. Even though no 
significant impact of gender was observed on age at diagnosis and outcomes, it should be 
emphasized that PAH mostly occurs in females, irrespective of BMPR2 status (sex ratio 
females:males = 2.4:1 in both BMPR2 mutation carriers and non-carriers). To explain over-
representation of female patients it has been suggested that estrogens and estrogen 
metabolism might be involved in the pathogenesis of PAH [West et al., 2008a; Austin et al., 
2009a; Mair et al., 2015]. These studies support the hypothesis that altered estrogen 
metabolism could contribute to the penetrance of PAH in women and suggest Cytochrome 
P450 1B1 (CYP1B1) as a sex-specific modifier gene. 
Similar findings are observed with ACVRL1 mutations with a significant number of 
pediatric cases and a dismal prognosis [Girerd et al., 2010a]. In this study, ACVRL1 mutation 
carriers were shown to be characterized by a younger age at PAH diagnosis (21.8 ± 16.7 
years) than BMPR2 mutation carriers and non-carriers (35.7 ± 14.9 and 47.6 ± 16.3 years, 
respectively; p <0.0001). However, ACVRL1-positive patients had better hemodynamic status 
at diagnosis, but none responded to acute vasodilator challenge. Thus, despite less severe 
initial hemodynamics and similar management, these patients had a worse prognosis than 
other patients with PAH, suggesting more rapid disease progression. 
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Most recently, a ‘two-hit’ model has been proposed, wherein digenic mutations may 
account for earlier occurrence, increased severity and more rapid deterioration of PAH 
patients [Wang et al., 2014]. 
 
Expansion of the Genetic Architecture of PAH by Next-Generation Sequence Analysis 
Caveolin 1 (CAV1) 
Whole-exome sequencing was used to study one large family with six PAH cases across 
three generations with autosomal dominant transmission and without known mutation. 
Specifically, the exomes of 4 of the 6 PAH patients were evaluated and following 
bioinformatic analyses 11 rare candidate variants were determined to be shared by all four 
patients in the family. Genetic analysis of an additional patient in the family supported the 
conclusion that a rare mutation in the CAV1 gene (PPH3; MIM# 615343) was of pertinence 
to disease. The observed mutation in exon 3 (c.474delA; p.L159Sfs*22), impacts a highly 
conserved region and predicts deleterious functional consequences. 
 An additional 62 independent PAH families and 198 unrelated idiopathic PAH patients, all 
without detectable TGF-β gene mutations, were screened for CAV1 mutations by Sanger 
sequencing. Of 260 patients one early-onset idiopathic patient harbored a de novo CAV1 
mutation in exon 3 of the gene (c.473delC; p.P158Hfs*23) (Table 4). Of note, identified 
variants were not present in over 1000 ethnically-matched Caucasian controls [Austin et al., 
2012]. 
 
Potassium Channel, Subfamily K, Member 3 (KCNK3) 
Most recently, whole-exome sequencing has led to the identification of KCNK3 as a risk 
factor for familial and idiopathic disease (PPH4; MIM# 615344). By screening three affected 
subjects from an autosomal dominant family negative for mutation in BMPR2, ACVRL1, 
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ENG, SMAD9 and CAV1, Ma et al. detected a novel coding variant of KCNK3 that was 
shared among all three subjects and predicted to be pathogenic by in silico bioinformatic 
tools. Subsequent Sanger sequencing across the extended family confirmed co-segregation of 
the disease with the c.608G>A (p.G203D) variant, which was absent from 100 ethnically 
matched control individuals [Ma et al., 2013]. Analysis of exome sequence from 10 further 
HPAH probands identified two additional novel heterozygous variants, which also segregated 
with disease, providing strong evidence for a role of KCNK3 in PAH pathogenesis. To assess 
the frequency of KCNK3 variation in familial and idiopathic disease, an extended cohort of 
82 HPAH and 230 IPAH cases were screened for mutation. Three novel heterozygous 
missense variants were detected in the idiopathic cohort, suggesting that KCNK3 mutation 
accounts for 1.3% of IPAH cases and 3.2% of HPAH families [Ma et al., 2013] (Table 4). 
 
Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4 (EIF2AK4) 
Similarly, exome sequencing has revealed several disease causing mutations in the 
EIF2AK4 gene in pulmonary veno-occlusive disease (PVOD) and pulmonary capillary 
hemangiomatosis (PCH), together classified as group 1′ of PAH in the most recent diagnostic 
classification [Simonneau et al., 2013]. Both conditions are inherited in an autosomal 
recessive manner (PVOD2; MIM# 234810) and are mainly characterized by proliferation of 
capillaries in the lung leading to an occlusion of pulmonary vasculature. Eyries et al. assessed 
five families with PVOD and focused on rare variants (minor allele frequency <0.1% in 
control populations), which were homozygous or compound heterozygous in affected 
children and heterozygous in unaffected parents. Using this analysis strategy, mutations in 
EIF2AK4 were identified in all 13 families studied. The examination of 20 sporadic cases 
revealed EIF2AK4 mutations in 5 additional patients [Eyries et al., 2014]. Mutations were 
distributed throughout the gene and belonged to the major mutation categories (Table 5). The 
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range of mutations situated upon this locus underlines its functional importance in the 
development of PVOD.  
In parallel, mutations in EIF2AK4 were independently identified by Best et al. in patients 
with heritable PCH. The exomes of two affected brothers were sequenced and filtered for 
variants with a minor allele frequency of less than 1% in public repositories of polymorphic 
data resulting in the identification of two pathogenic variants in the gene. The unaffected 
parents and sister were confirmed to be heterozygous carriers of one of the two mutations 
[Best et al., 2014]. Further sequencing of EIF2AK4 in 10 patients with pathologically verified 
sporadic PCH and one familial case detected three additional mutations in two sporadic 
patients (Table 5). The genetic correlation between PVOD and PCH further supports the 
likelihood that these diseases define different clinical spectra of the same underlying disorder. 
Most recently, EIF2AK4 has also been investigated in an itinerant Iberian population with 
PAH [Tenorio et al., 2015]. The authors identified a homozygous c.3344C>T (p.P1115L) 
missense mutation in five patients from five independent families with HPAH. Likely 
ancestral, this mutation co-segregated with a more severe phenotype than previously reported 
for other EIF2AK4 mutations. The majority of affected subjects presented with an early 
onset, aggressive form of the disease resulting in an abnormally low survival rate post-lung 
transplantation (1.1 years).  
 
 
Biological Significance of Mutations in Non-Canonical BMP Pathways 
While rare, the biologic plausibility for CAV1 mutations in PAH is strong. CAV1 encodes 
Caveolin-1, a membrane protein required to form the flask-shaped invaginations of the cell 
membrane known as caveolae, abundant in lung endothelial and mesenchymal cells [Minshall 
et al., 2003; Xu et al., 2008]. Caveolae are critical to a number of cellular processes and 
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receptor rich regions of the cell membrane [Nohe et al., 2005; Mercier et al., 2009; Chidlow 
and Sessa, 2010]. Intriguingly, mice haploinsufficient for Cav1 display pulmonary vascular 
disease analogous to PAH [Drab et al., 2001; Zhao et al., 2002; Murata et al., 2007; Maniatis 
et al., 2008]. Moreover, Caveolin-1 protein staining is reduced in lung endothelial cells from 
human PAH patients [Zhao and Malik, 2009]. Nevertheless, although under careful scrutiny, 
the precise mechanism(s) by which CAV1 mutations promote PAH remain unclear. 
The KCNK3 gene is located on chromosome 2p24 and encodes a pH-sensitive potassium 
channel with a role in regulation of resting membrane potential in a variety of cell types. 
Electrophysiological analyses demonstrated that all identified mutations lead to a loss of 
function as measured by current density. A subset of identified mutations (p.T8K, p.E182K 
and p.G203D) exhibited a significant increase in potassium-channel current when treated 
with the phospholipase inhibitor ONO-RS-082. The identification of this gene provides an 
additional avenue of treatment strategies for PAH. 
The EIF2AK4 gene encodes a kinase, which phosphorylates an initiation factor in protein 
synthesis that is primarily responsible for the translation of stress response proteins [Donnelly 
et al., 2013]. Interactions between the kinase and various members of the BMPR-II pathway 
have also been detected, but the exact link to the clinical manifestations of pulmonary veno-
occlusive PH remains to be clarified [Eyries et al., 2014]. The EIF2AK4 protein belongs to a 
family of kinases that regulate angiogenesis in response to cellular stress. Of interest, these 
properties are compatible with the angiogenic pathology of PCH, a disorder characterized by 
uncontrolled proliferation of pulmonary microvessels. 
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Modifying Predisposition to PAH:  
Cerebellin 2 Precursor (CBLN2) 
PAH demonstrates several complex traits including incomplete penetrance, sex bias and 
variable age of disease onset both within and across families. This has led to the hypothesis 
that modifier genes contribute to disease manifestation and/or progression. To examine the 
role of common variation in PAH predisposition, Germain et al. performed a genome-wide 
association study (GWAS) to identify susceptibility loci in IPAH and HPAH cases without 
BMPR2 mutation. The discovery dataset comprised 340 PAH patients and 1,068 healthy 
controls, genotyped for ~470,000 variants, from which the 384 most significant variants were 
assessed in an independent replication cohort of 285 cases and 457 controls. This approach, 
which represents the best powered study to date, identified two variants 52 kb downstream of 
the CBLN2 gene that were associated with a two-fold increased risk of disease [Germain et 
al., 2013]. 
CBLN2 encodes a secreted neuronal glyocoprotein primarily expressed in the brain. 
However, real-time PCR studies demonstrated CBLN2 mRNA expression in the whole lung, 
significantly higher in explants from PAH patients comparative to histologically normal lung 
tissue. Similar results were obtained for pulmonary arterial endothelial cells. Furthermore, an 
inhibition of pulmonary artery smooth muscle cell (PASMC) proliferation was observed 
when treated with increasing concentrations of CBLN2 peptide [Germain et al., 2013].  
 
Potassium Channel, Voltage Gated Shaker Related Subfamily A, Member 5 (KCNA5) 
Membrane potential is essential for contraction and vasodilation of PASMCs. Expression 
of potassium channels is regulated by BMP signaling in vitro and in vivo and knockouts in 
Drosophila melanogaster result in defects that are strikingly similar to phenotypes that result 
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from disrupted TGF-β/BMP signaling [Young et al., 2006; Dahal et al., 2012]. Variation of 
the potassium channel KCNA5 has been identified in IPAH patients [Remillard et al., 2007; 
Wang et al., 2014] suggesting a potential role in PAH development and penetrance. The 
potassium channel response in PASMCs of IPAH patients has been proven to be down 
regulated [Yuan et al., 1998] likely increasing pulmonary vasoconstriction and PASMC 
proliferation. Moreover, the channel, which is responsive to nitric oxide, is reduced in 
patients carrying a specific coding missense mutation [Remillard et al., 2007]. Mutations 
within KCNA5 have been identified as a so-called ‘second hit’ in an index patient additional 
to a BMPR2 missense mutation leading to an early onset and severe phenotype [Wang et al., 
2014]. While these findings may represent a rare case of genetic modification in PAH, 
replication of this digenic genotype in an independent cohort has not been observed. Further, 
in the absence of comprehensive functional analysis, interpretation of the significance of this 
study requires caution. 
 
Animal Models of PAH 
Model systems of PAH serve a two-fold purpose in providing 1) a source of relevant, 
genetically modified cell types for in vitro studies, and 2) an in vivo platform for the analysis 
and refinement of direct therapeutic intervention. Several natural and engineered models of 
disease exist, for example, the fawn-hooded rat and the Bmpr2 transgenic mouse over-
expressing the p.R899* mutant allele, the latter being generated by introduction of a smooth 
muscle-specific doxycycline-inducible mutant transgene [West et al., 2008b; Ryan et al., 
2011]. Further, knock-out models lacking exons 4 and 5 of Bmpr2 generated by homologous 
recombination have been developed. These models develop mild to moderate disease 
phenotypes, often upon the application of environmental insults including exposure to 
hypoxia and 5-lipoxygenase as previously described [Machado et al., 2006]. Conditional 
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targeting of mutant alleles to hallmark sites of damage in PAH, in particular the pulmonary 
artery endothelial or smooth muscle cell layers, has produced a more convincing in vivo 
reflection of the human disease state [West et al., 2004; Hong et al., 2008]. Most recently a 
heterozygous knock-in mouse model of the p.R899* mutation has been shown to develop 
age-related disease with close phenotypic relatedness to the human condition [Long et al., 
2015]. Additionally a rat model of PAH (BMPR2Δ140Ex1/+), the first of its kind, has provided 
support to the hypothesis that endothelial-to-mesenchymal transition represents a 
pathophysiological process in PAH [Ranchoux et al., 2015]. Of note, mice representative of 
recently observed defects in previously uncharacterized genes, namely Cav1 and Smad9, 
support the emerging concept of greater than anticipated genetic heterogeneity in PAH. 
Homozygous knock-out models of both genes develop spontaneous indications of PAH 
providing a powerful correlation to the human studies described herein [Zhao et al., 2002; 
Huang et al., 2009]. 
 
Genetic Counseling 
Current guidelines recommend offering molecular genetic analysis and genetic counseling 
for HPAH patients [Badesch et al., 2007; McLaughlin et al., 2009]. Genetic counseling 
typically offers a combinatorial approach of dealing with putative outcomes and 
consequences of the analysis, based upon structured protocols determined by specialist 
centers evaluates the family history, educates patients about the causes of PAH, discusses the 
risks and benefits of genetic testing and supports patients and families through the process of 
genetic testing and disclosure of results. In addition to HPAH patients, IPAH patients and 
their relatives may also benefit from these analyses since up to 25% will have a BMPR2 
mutation; therefore, genetic testing in these populations should be considered [Badesch et al., 
2007]. Current findings indicate that in patient populations with PVOD and PCH, autosomal 
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recessive inheritance of the EIF2AK4 gene is the most likely mode of transmission. Hence, 
within the PAH spectrum of disease, based on current classification, genetic counseling 
should take account of both autosomal dominant and recessive  inheritance models, as well as 
the higher penetrance of bi-allelic mutations in patients carrying this genetic defect. 
Following identification of an established molecular defect in the proband, at-risk 
asymptomatic family members should be offered the option of genetic counseling and 
targeted mutation analysis within the parameters of full informed consent. Importantly, the 
data provided here offer an indication of the likely pathogenicity of identified variation. A 
significant factor to consider is the reduced penetrance of mutant alleles which must be 
addressed by informed pre-test counseling, comprising robust estimations of risk based on 
available population-specific epidemiological data and gender [Cogan et al., 2012; Larkin et 
al., 2012]. Of note, where a mutation is identified, implications for reproductive planning 
must be considered. In families harboring mutation, early mutational analysis of offspring is 
essential and should be combined with clinical assessment and initiation of treatment as 
deemed necessary by specialist centers. Additionally, a possible future avenue of medical 
care has been explored. Within a BMPR2-positive family, pre-implantation genetic analysis 
of blastomeres following in vitro fertilization led to the successful implantation and delivery 
of a mutation-negative offspring [Frydman et al., 2012]. Although in its earliest stages this 
strategy is of significant clinical potential in the context of considered, long-term genetic 
evaluation. 
 
Diagnostic Strategies 
Molecular diagnostics for PAH have traditionally focused around dideoxy Sanger 
sequencing methods to screen the BMPR2, ACVRL1 and ENG protein-coding regions for 
heterozygous mutation. However, based on these and previous studies, for a complete 
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exploration of deletion and duplication across these three genes, the application of MLPA or 
targeted comparative genomic hybridization (CGH) array technology is required. The 
HHT/PPH1 MLPA panel was introduced by MRC-Holland in the mid-2000s, with the current 
version containing 51 probes across BMPR2, ACVRL1 and ENG, and has led to the successful 
detection of numerous gene rearrangements that would otherwise not be identified by 
sequence analysis [Aldred et al., 2006; Cogan et al., 2006]. 
 Despite the success of this combined approach to mutation detection in PAH, the recent 
expansion of candidate disease genes has resulted in traditional sequencing methods 
becoming more labor-intensive and less cost-effective. Indeed, to comprehensively screen the 
10 genes detailed here would involve sequencing approximately 105 coding exons, totaling 
over 19 kb of DNA sequence. Custom capture and NGS are now becoming chosen 
methodologies across screening centers globally for the analysis of established candidate 
genes. 
 
Future Prospects 
It is clear that the most significant advance in the identification of risk factors for PAH 
over recent years has been the advent of exome sequencing, which has led to the rapid 
identification of multiple novel genes using relatively small sample sets. Whilst exome 
sequencing is undoubtedly a powerful method for detecting rare, highly penetrant genes in 
families with multiple affected individuals, there remain important caveats in applying these 
technologies to the identification of novel genes across cohorts of unrelated subjects and 
genetically divergent patient groups. In PAH, complexities such as locus heterogeneity, 
incomplete penetrance, de novo mutation and late onset of disease introduce significant 
challenges to the interpretation of exome sequence data, highlighting the need for large 
homogeneous patient cohorts to detect pathogenic variation. In terms of technical limitations, 
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exome sequencing also only focuses on the exonic regions. While these regions represent the 
most likely sites of functional mutations in PAH, there is increasing evidence supporting 
pathogenic variants in the promoter and 5′ UTR of BMPR2, suggesting this may also be true 
of other PAH genes. A recent report by Hinderhofer et al. has also identified an intronic 
mutation of BMPR2 that leads to aberrant splicing due to an insertion of an intronic Alu 
element 26 bp upstream from exon 6 [Hinderhofer et al., 2014]. This points to a potential role 
for other intronic variants or regulatory elements such as intra- or intergenic enhancer and 
repressor motifs in the pathogenesis of PAH.  
To address some of these issues, it is likely that future avenues will include the use of 
more NGS technologies, the pinnacle of which is whole-genome sequencing. Harnessing the 
complete genetic information of individuals affected with PAH will not only offer 
opportunities to identify the causative mutation but will also provide an important tool to 
correlate phenotypic information to individual genotype data, allowing for tailored 
approaches to the clinical management of disease, or so-called personalized or precision 
medicine. While this technology remains financially prohibitive to some centers, custom 
capture of genes with defined causal links to disease offers an alternative, yet powerful, 
means of analyses. These studies would, ideally, include non-coding sections of the genes to 
determine the presence of regulatory mutations increasingly implicated in PAH etiology as 
described herein. The catalogue of mutations described in this report provides an important 
tool for the determination of deleterious mutation, both within the context of conventional 
and indeed NGS analyses. 
For future gene identification and follow-up GWAS studies, it is of particular importance 
in PAH, which exhibits traits of complex disease, that phenotype is precisely assigned for this 
disorder. This degree of rigor is most likely to lead to further advances in both the 
understanding and treatment of PAH at a significantly accelerated pace.  
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Figure 1. Schematic of canonical BMP signaling and additional pathways implicated in PAH 
pathogenesis by conventional and next-generation sequence analysis. Causal genes are 
indicated by the asterisks. 
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Figure 2. A) Distribution of reported exonic mutations across the BMPR2 gene. Black bars 
represent all mutation categories; grey bars indicate missense mutations only. This graph 
excludes data from non-coding regions and gene rearrangements for which start and/or 
end points have not been conclusively determined. B) Proportion of distinct point 
mutations relative to exon size. Multiple and/or recurrent variants at the same nucleotide 
were counted as a single event. The total number of mutated residues confined to the 
open-reading frame was calculated as a percentage of exon length in nucleotides. 
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Figure 3. Three-dimensional structure of the BMPR-II extracellular domain highlighting the 
location of substitutions impacting upon 9 of the 10 key cysteine residues responsible for 
disulfide bridge formation, indicated in dark blue. Defects in the Cys116 residue have not 
been identified in PAH thus far. Figure was reproduced from the crystal structure (PDB 
ID: 2HLQ) and processed using Cn3D v4.3 software. 
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Table 1. Novel pathogenic BMPR2 mutations identified in this analysis 
Location Mutation category Nucleotide change† Amino acid change Frequency in this study‡ Clinical classification 
5'UTR Transition c.-669G>A p.? 3 I, NK, P 
5'UTR to exon 1 Deletion c.?_-540_76+?del p.? 1 NK 
5'UTR to exon 13 Deletion c.?_-540_3117+?del p.? 1 NK 
Exon 1 Deletion c.1-?_76+?del p.? [3] I, NK (n=2) 
Exon 1 Frameshift c.9dupC p.S4Lfs*34 1 NK 
Exon 1 Nonsense c.16C>T p.Q6* 2 I, NK 
Exon 1 Nonsense c.38G>A p.W13* 1 H 
Exon 1 Nonsense c.48G>A p.W16* 1 I 
Intron 1 Splice-site c.76+1G>T p.? 1 H 
Intron 1 Splice-site c.76+2T>C p.? 1 NK 
Intron 1 Splice-site c.77-1G>A p.A26Efs*9 1 H 
Exons 2-5 Deletion c.77-?_621+?del p.? 1 H 
Exons 2-9 Deletion c.77-?_1276+?del p.? 1 NK 
Exon 2 Nonsense c.82C>T p.Q28* 1 NK 
Exon 2 Missense c.178T>C p.C60R 1 NK 
Exon 2 Missense c.196T>G p.C66G 1 NK 
Exon 2 Frameshift c.236_238delinsAAAAGGGGACA p.L79Qfs*5 1 NK 
Exon 2 Frameshift c.246dupA p.G83Rfs*15 1 H 
Intron 2 Splice-site c.247+1G>A p.? 1 NK 
Exon 3 Deletion c.248-?_418+?del p.? [4] I (n=3), NK 
Exon 3 Duplication c.248-?_418+?dup p.? 1 H 
Exon 3 Missense c.280T>G p.C94G 1 NK 
Exon 3 Frameshift c.339_340insAA p.R114Nfs*39 1 H 
Exon 3 Frameshift c.345_346delCT p.F115Lfs*4 1 NK 
Exon 3 Missense c.350G>A p.C117Y 1 NK 
Exon 3 Frameshift c.353delG p.C118Lfs*34 1 NK 
Exon 3 Missense c.354T>G p.C118W 1 I 
Exon 3 Missense c.377A>G p.N126S 1 NK 
Exon 4 Deletion c.419-?_529+?del p.? 1 NK 
Exons 4-7 Deletion c.419-?_967+?del p.? [2] I, NK 
Exons 4-10 Deletion c.419-?_1413+?del p.? 1 NK 
Exon 4 Frameshift c.435delT p.F145Lfs*7 1 NK 
Exon 4 Nonsense c.439C>T p.R147* 1 H 
Exon 4 Nonsense c.482T>A p.L161* 1 I 
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Exon 5 Deletion c.530-?_621+?del p.? 1 NK 
Exon 5 Nonsense c.541C>T p.Q181* 1 H 
Exon 6 Nonsense c.637C>T p.R213* 1 H 
Exon 6 Nonsense c.642T>G p.Y214* 1 NK 
Exon 6 Frameshift c.673_679delCGTCCAG p.R225Lfs*3 1 H 
Exon 6 Nonsense c.727G>T p.E243* 1 I 
Exon 6 Frameshift c.795_796delinsTT p.E265_L1038delinsD 1 NK 
Intron 6 Splice-site c.853-2A>G p.? 1 NK 
Intron 6 Splice-site c.853-1G>A p.? 1 NK 
Exon 7 Nonsense c.860T>A p.L287* 1 H 
Exon 7 Nonsense c.872T>G p.L291* 1 NK 
Exon 7 Nonsense c.893G>A p.W298* 1 NK 
Exon 7 Frameshift c.894_895dupGG p.V299Gfs*2 1 H 
Exon 7 Frameshift c.961delC p.R321Efs*14 1 NK 
Intron 7 Splice-site c.967+2T>C p.? 1 H 
Intron 7 Splice-site c.968-3C>G p.? 1 NK 
Intron 7 Splice-site c.968-1G>T p.? 1 NK 
Exon 8 Nonsense c.994C>T p.R332* 1 NK 
Exon 8 Frameshift c.1011_1015delAAATG p.R337Sfs*6 1 I 
Exon 8 Frameshift c.1060delC p.L354Cfs*3 1 NK 
Exon 8 Nonsense c.1126G>T p.E376* 2 I, NK 
Exon 9 Frameshift c.1129-1_1129dupGG p.V377Gfs*13 1 I 
Exon 9 Frameshift c.1141dupA p.R381Kfs*18 1 H 
Exon 9 Missense c.1156G>C p.E386Q 1 NK 
Exon 9 Missense c.1220A>C p.Y407S 1 NK 
Exon 9 Nonsense c.1221T>G p.Y407* 1 H 
Exon 9 Frameshift c.1268dupT p.F424Lfs*24 1 NK 
Exon 9 Missense c.1276G>C p.G426R 1 H 
Intron 9 Splice-site c.1277-9A>C p.? 1 H 
Intron 9 Splice-site c.1277-8A>G p.? 1 NK 
Exon 10 Frameshift c.1279delG p.E427Nfs*47 1 NK 
Exon 10 Frameshift c.1285_1286insGGATT p.V429Gfs*47 2 I, NK 
Exon 10 Frameshift c.1293_1300delGTACCAGA p.E431Dfs*14 1 NK 
Exon 10 Frameshift c.1371delA p.K457Nfs*17 1 H 
Exon 10 Nonsense c.1398G>A p.W466* 1 NK 
Exon 10 Nonsense c.1402G>T p.E468* 1 H 
Exon 11 Frameshift c.1426_1450del p.L476Gfs*22 1 NK 
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Exon 11 Nonsense c.1441G>T p.E481* 1 NK 
Exon 11 Nonsense c.1451G>A p.W484* 1 H 
Exon 11 Missense c.1453G>A p.D485N 1 P 
Exon 11 Nonsense c.1456C>T p.Q486* 1 H 
Exon 11 Frameshift c.1477dupA p.T493Nfs*6 1 NK 
Exon 11 Missense c.1486T>C p.C496R 1 NK 
Intron 11 Splice-site c.1587-7_1587-4delCTTT p.? 1 I 
Exon 12 Nonsense c.1629T>G p.Y543* 1 I 
Exon 12 Nonsense c.1750C>T p.R584* 1 NK 
Exon 12 Nonsense c.1789C>T p.R597* 1 NK 
Exon 12 Nonsense c.1969C>T p.Q657* 2 I, NK 
Exon 12 Nonsense c.1981G>T p.E661* 1 NK 
Exon 12 Frameshift c.2291dupA p.N764Kfs*49 1 H 
Exon 12 Frameshift c.2303_2309delAGCCCCG p.E768Gfs*2 1 NK 
Exon 12 Frameshift c.2308delC p.R770Gfs*2 2 NK (n=2) 
Exon 12 Frameshift c.2484delG p.T829Qfs*10 1 H 
Exon 12 Nonsense c.2533G>T p.E845* 1 I 
Exon 12 Nonsense c.2695C>T p.R899* 3 H (n=2), NK 
Exon 12 Nonsense c.2730T>A p.C910* 1 H 
Exon 12 Nonsense c.2737C>T p.Q913* 1 I 
 
†GenBank reference sequence and version number for BMPR2: NM_001204.6; numbering is from +1 as A of the ATG initiation codon 
‡Total number of independent cases. Frequencies in square brackets denote chromosomal rearrangements for which the breakpoints are unknown 
and may therefore represent distinct mutations 
Key to abbreviations: H: heritable pulmonary arterial hypertension; I: idiopathic pulmonary arterial hypertension; NK: not known; P: pediatric 
pulmonary arterial hypertension 
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Table 2. BMPR2 variants of uncertain pathological significance 
Location Mutation 
category 
Nucleotide 
change† 
Amino acid 
change 
Clinical 
classification 
Domain Reference Population 
frequency 
a) PolyPhen-2 b) PROVEAN c) SIFT 
Prediction Score Prediction Score Prediction Score 
Exon 3 Missense c.266G>C p.G89A HPAH ECD Liu et al., 2012 - Possibly 
damaging 
0.638 Neutral -1.785 Tolerated 0.137 
Exon 3 Missense c.276A>C p.Q92H HPAH ECD Kabata et al., 2013 0.0001071 Benign 0.001 Neutral  -1.388 Tolerated  0.311 
Exon 3 Missense c.292G>A p.E98K IPAH ECD Wang et al., 2010 - Possibly 
damaging 
0.515 Neutral  -1.792 Tolerated  0.092 
Exon 4 Missense c.461C>G p.A154G IPAH TM Pfarr et al., 2011 - Benign 0.025 Neutral -1.994 Damaging 0.032 
Exon 6 Missense c.818T>G p.M273R IPAH KD Pfarr et al., 2011 - Benign 0.004 Deleterious -2.716 Tolerated 0.213 
Exon 7 Missense c.901T>C p.S301P NK (n=2) KD Sztrymf et al., 2008; 
Girerd et al., 2010b 
- Benign 0.046 Neutral -2.19 Tolerated 0.086 
Exon 7 Missense c.954A>C p.E318D HPAH KD This analysis - Benign 0.089 Neutral -0.347 Tolerated 0.273 
Exon 8 Missense c.1042G>A p.V348I HPAH; 
IPAH (n=2) 
KD Wang et al., 2010; 
Liu et al., 2012 
0.0004550 Possibly 
damaging 
0.715 Neutral -0.45 Damaging 0.023 
Exon 8 Missense c.1066A>T p.M356L IPAH KD Wang et al., 2010 - Benign 0.023 Neutral -0.497 Tolerated 0.417 
Exon 8 Missense c.1117G>C p.A373P IPAH KD Liu et al., 2012 - Probably 
damaging 
0.99 Neutral -2.493 Tolerated 0.087 
Exon 11 Missense c.1516A>G p.M506V IPAH CD This analysis 0.0000412 Benign 0.008 Neutral -0.896 Tolerated 0.244 
Exon 12 Missense c.1598A>G p.H533R IPAH CD Pfarr et al., 2011 - Benign 0.267 Neutral -2.049 Damaging 0.021 
Exon 12 Missense c.1766A>G p.Y589C CHD-APAH 
(exercise-
induced) (n=2) 
CD Möller et al., 2010 0.0001320 Probably 
damaging 
0.999 Deleterious -3.436 Damaging 0.001 
Exon 12 Missense c.2296A>G p.T766A IPAH; 
CTEPH 
CD Liu et al., 2012; 
Feng et al., 2014 
0.0000083 Benign 0 Neutral -0.183 Tolerated 0.424 
Exon 12 Missense c.2618G>A p.R873Q NK (n=2) CD Sztrymf et al., 2008; 
Girerd et al., 2010b 
0.0001153 Probably 
damaging 
0.966 Neutral -0.861 Tolerated 0.128 
 
Population frequency data were obtained from the ExAC database (http://exac.broadinstitute.org/gene/ENSG00000204217). The likely 
pathogenicity of each missense variant was calculated by three in silico prediction methods, using the default parameters in each case. Ranges 
and cut-offs for output scores were as follows: a) PolyPhen-2 v2.2.2 (http://genetics.bwh.harvard.edu/pph2). Range: 0 – 1 [benign: 0 – 0.452; 
possibly damaging: 0.453 – 0.956; probably damaging: 0.957 – 1]; b) PROVEAN Human Protein v1.1 
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(http://provean.jcvi.org/protein_batch_submit.php?species=human). Cut-off: -2.5 [deleterious: ≤-2.5; neutral: >-2.5]; c) SIFT Human Protein 
v1.03 (PROVEAN Protein batch input). Range: 0 – 1 [damaging: ≤0.05; tolerated: >0.05]. 
†GenBank reference sequence and version number for BMPR2: NM_001204.6; numbering is from +1 as A of the ATG initiation codon. 
Key to abbreviations: CD: cytoplasmic tail domain; CHD-APAH: congenital heart disease-associated pulmonary arterial hypertension; 
CTEPH: chronic thromboembolic pulmonary hypertension; ECD: extracellular ligand-binding domain; HPAH: heritable pulmonary arterial 
hypertension; IPAH: idiopathic pulmonary arterial hypertension; KD: kinase domain; NK: not known; TM: transmembrane domain 
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Table 3. PAH mutations identified in BMP pathway members 
Gene 
name 
Location Mutation 
category 
Nucleotide change† Amino acid 
change 
Frequency in 
this study‡ 
Clinical classification Reference(s) 
ACVRL1 Exon 2 Frameshift c.37delC p.L13Cfs*2 1 PAH-HHT Trembath et al., 2001; Girerd et al., 2010a 
ACVRL1 Exon 3 Missense c.199C>T p.R67W 1 PAH-HHT Chen et al., 2013 
ACVRL1 Exon 3 Missense c.293A>G p.N98S 1 NK This analysis 
ACVRL1 Exon 4 Nonsense c.430C>T p.R144* 1 I Machado et al., 2009 
ACVRL1 Exon 5 Missense c.536A>C p.D179A 1 I Harrison et al., 2003^ 
ACVRL1 Exon 5 Missense c.593T>A p.V198E 1 PAH-HHT Chen et al., 2013 
ACVRL1 Exon 5 Missense c.602A>G p.Q201R 1 PAH-HHT Girerd et al., 2010a 
ACVRL1 Exon 6 Missense c.632G>A p.G211D 1 PAH-HHT Harrison et al., 2003 
ACVRL1 Exon 6 Missense c.653_654inv p.R218P 1 PAH-HHT Chen et al., 2013 
ACVRL1 Exon 6 Deletion c.760_762delGAC p.D254del 1 PAH-HHT Trembath et al., 2001 
ACVRL1 Exon 7 Missense c.788A>G p.D263G 1 PAH-HHT This analysis 
ACVRL1 Exon 7 Missense c.818T>C p.L273P 1 PAH-HHT Smoot et al., 2009 
ACVRL1 Exon 7 Missense c.853C>T p.L285F 1 NK This analysis 
ACVRL1 Exon 7 Missense c.854T>C p.L285P 1 P Chida et al., 2012b 
ACVRL1 Exon 7 Missense c.936C>G p.H312Q 1 P Fujiwara et al., 2008^ 
ACVRL1 Exon 7 Missense c.950T>C p.I317T 1 P Pfarr et al., 2013 
ACVRL1 Exon 7 Missense c.955G>C p.G319R 1 NK This analysis 
ACVRL1 Exon 7 Missense c.1031G>A p.C344Y 2 PAH-HHT (n=2) Harrison et al., 2003 
ACVRL1 Exon 8 Missense c.1055C>A p.A352D 2 PAH-HHT (n=2) Smoot et al., 2009 
ACVRL1 Exon 8 Missense c.1120C>T p.R374W 3 PAH-HHT (n=2), NK Harrison et al., 2003; Abdalla et al., 2004; This 
analysis 
ACVRL1 Exon 8 Missense c.1121G>A p.R374Q 2 PAH-HHT (n=2) Harrison et al., 2003; Chen et al., 2013 
ACVRL1 Exon 8 Missense c.1124A>G p.Y375C 1 PAH-HHT Chen et al., 2013 
ACVRL1 Exon 8 Missense c.1142T>C p.L381P 1 P Fujiwara et al., 2008^ 
ACVRL1 Exon 8 Missense c.1195T>C p.W399R 1 PAH-HHT Chen et al., 2013 
ACVRL1 Exon 8 Missense c.1196G>C p.W399S 1 PAH-HHT Harrison et al., 2003 
ACVRL1 Exon 8 Missense c.1196G>T p.W399L 1 PAH-HHT Ishiwata et al., 2014 
ACVRL1 Exon 8 Missense c.1231C>T  p.R411W 1 PAH-HHT Trembath et al., 2001 
ACVRL1 Exon 8 Missense c.1232G>A p.R411Q 1 PAH-HHT Harrison et al., 2003 
ACVRL1 Exon 9 Missense c.1270C>A p.P424T 1 P Fujiwara et al., 2008^ 
ACVRL1 Exon 9 Missense c.1280A>T p.D427V 1 PAH-HHT Girerd et al., 2010a 
ACVRL1 Exon 9 Missense c.1324G>A p.V442M 1 PAH-HHT Girerd et al., 2010a 
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ACVRL1 Exon 10 Nonsense c.1385C>G p.S462* 1 PAH-HHT Abdalla et al., 2004 
ACVRL1 Exon 10 Frameshift c.1388delG p.G463Afs*2 1 PAH-HHT Girerd et al., 2010a 
ACVRL1 Exon 10 Frameshift; 
Nonsense 
c.1388delG; 
c.1390delC 
p.G463Afs*2; 
p.L464* 
1 PAH-HHT (mosaic) Eyries et al., 2012 
ACVRL1 Exon 10 Missense c.1433C>A p.A478D 1 P Chida et al., 2012b 
ACVRL1 Exon 10 Nonsense c.1435C>T p.R479* 2 PAH-HHT (n=2) Abdalla et al., 2004; Chen et al., 2013 
ACVRL1 Exon 10 Missense c.1436G>A p.R479Q 1 P Fujiwara et al., 2008^ 
ACVRL1 Exon 10 Missense c.1436G>C p.R479P 1 I Machado et al., 2009 
ACVRL1 Exon 10 Missense c.1450C>G p.R484G 1 H Jones et al., 2014 
ACVRL1 Exon 10 Missense c.1450C>T p.R484W 2 PAH-HHT (n=2) Trembath et al., 2001; Girerd et al., 2010a 
ACVRL1 Exon 10 Frameshift c.1450delinsTG p.R484Wfs*10 1 PAH-HHT Abdalla et al., 2004 
ACVRL1 Exon 10 Missense c.1451G>A p.R484Q 7 P (n=2); PAH-HHT (n=3; 
1 mosaic); NK (n=2) 
Harrison et al., 2005^; Fujiwara et al., 2008^; 
Best et al., 2011; Chen et al., 2013; Pfarr et al., 
2013; This analysis 
ACVRL1 Exon 10 Missense c.1460A>C p.K487T 1 PAH-HHT Harrison et al., 2003 
ACVRL1 Exon 10 Nonsense c.1468C>T p.Q490* 1 PAH-HHT Trembath et al., 2001; Girerd et al., 2010a 
       
 
ENG Exon 5 Missense c.640G>A p.G214S 1 P Pfarr et al., 2013 
ENG Exon 5 Frameshift c.682_686delTCGGC p.S228Rfs*104 1 PAH-HHT Harrison et al., 2003^ 
ENG Exon 6 Missense c.788T>A p.I263N 1 PAH-HHT Chen et al., 2013 
ENG Exon 11 Frameshift c.1334delT p.M445Rfs*46 1 PAH-HHT Harrison et al., 2003^ 
ENG Exon 11 Frameshift c.1410delG p.Q471Sfs*20 1 PAH-HHT + 
dexfenfluramine 
Chaouat et al., 2004^ 
ENG Exon 12 Missense c.1633G>A p.G545S 1 CHD-PAH Pfarr et al., 2013 
ENG Intron 13 Branch-site c.1742-22T>C p.C582_R618del 1 PAH-HHT Harrison et al., 2005^; Mache et al., 2008^ 
ENG Exon 14 Frameshift c.1804delA p.I602Sfs*38 1 PAH-HHT Chen et al., 2013 
ENG Exon 15 Missense c.1853G>T p.R618L 1 I This analysis 
       
 
SMAD1 Exon 2 Missense c.8T>C p.V3A 1 I Nasim et al., 2011 
       
 
SMAD4 Exon 2 Missense c.38A>G p.N13S 1 I Nasim et al., 2011 
SMAD4 Intron 11 Splice-site c.1448-6T>C p.? 1 I Nasim et al., 2011 
       
 
SMAD9 Exon 2 Missense c.127A>G p.K43E 1 I Nasim et al., 2011 
SMAD9 Exon 3 Nonsense c.606C>A p.C202* 1 I Shintani et al., 2009 
SMAD9 Exon 5 Nonsense c.880C>T p.R294* 1 H Drake et al., 2011 
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†GenBank reference sequence and version number for ACVRL1: NM_000020.2; ENG: NM_001114753.2; SMAD1: NM_005900.2; SMAD4: 
NM_005359.5; SMAD9: NM_001127217.2 
‡Total number of independent cases 
^Previously reported in Machado et al., 2009 
 
Key to abbreviations: H: heritable pulmonary arterial hypertension; I: idiopathic pulmonary arterial hypertension; NK: not known; P: pediatric 
pulmonary arterial hypertension; PAH-HHT: pulmonary arterial hypertension with hereditary hemorrhagic telangiectasia 
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Table 4. PAH mutations identified in non-canonical BMP pathways 
Gene 
name 
Location Mutation category Nucleotide change† Amino acid change Frequency in 
this study‡ 
Clinical 
classification 
Reference(s) 
CAV1 Exon 3 Frameshift c.473delC p.P158Hfs*23 1 I Austin et al., 2012 
CAV1 Exon 3 Frameshift c.474delA p.L159Sfs*22 1 H Austin et al., 2012 
       
 
KCNA5 Exon 1 Missense c.544G>A p.G182R 2 I Remillard et al., 2007 
KCNA5 Exon 1 Missense c.633G>C p.E211D 2 I Remillard et al., 2007 
KCNA5 Exon 1 Frameshift c.1448delA p.Y483Sfs*4 1 H Wang et al., 2014^ 
       
 
KCNK3 Exon 1 Missense c.23C>A p.T8K 1 I Ma et al., 2013 
KCNK3 Exon 2 Missense c.289G>A p.G97R 1 H Ma et al., 2013 
KCNK3 Exon 2 Missense c.544G>A p.E182K 1 I Ma et al., 2013 
KCNK3 Exon 2 Missense c.575A>G p.Y192C 1 I Ma et al., 2013 
KCNK3 Exon 2 Missense c.608G>A p.G203D 1 H Ma et al., 2013 
KCNK3 Exon 2 Missense c.661G>C p.V221L 1 H Ma et al., 2013 
 
†GenBank reference sequence and version number for CAV1: NM_001753.4; KCNA5: NM_002234.3; KCNK3: NM_002246.2 
‡Total number of independent cases 
^Reported as a compound heterozygote with a BMPR2 c.1471C>T (p.R491W) mutation 
Key to abbreviations: H: heritable pulmonary arterial hypertension; I: idiopathic pulmonary arterial hypertension  
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Table 5. PVOD/PCH mutations identified in EIF2AK4 
Location Mutation category Nucleotide change† Amino acid change Frequency in 
this study‡ 
Clinical 
classification 
Reference(s) 
Exon 3; Intron 9 Frameshift; Splice-site c.354_355delTG; c.1554-4C>A p.C118Wfs*7; p.C519Dfs*17 1 PVOD-F Eyries et al., 2014 
Exon 5 Frameshift c.560_564delAAGAA; 
c.560_564delAAGAA 
p.K187Rfs*9; p.K187Rfs*9 1 PVOD-S Eyries et al., 2014 
Exon 5 Frameshift c.567dupG; c.567dupG p.K190Efs*8; p.K190Efs*8 1 PVOD-F Eyries et al., 2014 
Exon 7; Exon 12 Nonsense; Frameshift c.745C>T; c.2136_2139dupCACT p.R249*; p.S714Hfs*21 1 PVOD-F Eyries et al., 2014 
Intron 7; Exon 25 Splice-site; Nonsense c.860-1G>A; c.3448C>T p.?; p.R1150* 1 PCH Best et al., 2014 
Exon 9; Exon 28 Frameshift; Nonsense c.1153dupG; c.3766C>T p.V385Gfs*30; p.R1256* 1 PCH Best et al., 2014 
Exon 9 Nonsense c.1387C>T; c.1387C>T p.R463*; p.R463* 1 PVOD-F Eyries et al., 2014 
Exon 9; Exon 23 Nonsense; Nonsense c.1387C>T; c.3244C>T p.R463*; p.Q1082* 1 PVOD-F Eyries et al., 2014 
Exon 9 Frameshift c.1392delT; c.1392delT p.R465Vfs*38; p.R465Vfs*38 1 PCH Best et al., 2014 
Exon 9; Exon 28 Frameshift; Nonsense c.1392delT; c.3802C>T p.R465Vfs*38; p.Q1268* 1 PVOD-F Eyries et al., 2014 
Exon 11 Missense c.1754G>A; c.1754G>A p.R585Q; p.R585Q 1 PVOD-F Eyries et al., 2014 
Exon 12 Missense c.1928T>G; c.1928T>G p.L643R; p.L643R 1 PVOD-F Eyries et al., 2014 
Intron 13 Splice-site c.2319+1G>A; c.2319+1G>A p.?; p.? 1 PVOD-F Eyries et al., 2014 
Exon 15 Nonsense c.2458C>T; c.2458C>T p.R820*; p.R820* 1 PVOD-S Eyries et al., 2014 
Exon 19; Intron 25 Nonsense; Splice-site c.2857C>T; c.3576+1G>T p.Q953*; p.? 1 PVOD-S Eyries et al., 2014 
Exon 21 Splice-site c.3159G>A; c.3159G>A p.K975_K1053del; p.K975_K1053del 2 PVOD-F, -S Eyries et al., 2014 
Exon 23 Missense c.3344C>T; c.3344C>T p.P1115L; p.P1115L 5 H Tenorio et al., 2014 
Exon 24 Nonsense c.3406C>T; c.3406C>T p.R1136*; p.R1136* 1 PVOD-F Eyries et al., 2014 
Exon 25; Intron 36 Nonsense; Splice-site c.3448C>T; 
c.4728+1_4728+13delinsTTCT 
p.R1150*; p.? 1 PVOD-F Eyries et al., 2014 
Intron 29 Splice-site c.4065+1G>C; c.4065+1G>C p.?; p.? 1 PVOD-F Eyries et al., 2014 
Exon 31 Frameshift c.4205dupT; c.4205dupT p.S1403Kfs*45; p.S1403Kfs*45 1 PVOD-S Eyries et al., 2014 
 
†GenBank reference sequence and version number for EIF2AK4: NM_001013703.3 
‡Total number of independent cases 
Key to abbreviations: H: heritable pulmonary arterial hypertension; PCH: pulmonary capillary hemangiomatosis; PVOD: pulmonary veno-
occlusive disease (-F: familial; -S: sporadic) 
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Supp. Table S1.  Previously reported pathogenic BMPR2 mutations identified in pulmonary arterial hypertension 
Location Mutation 
category 
Nucleotide change
†
 Amino acid change Frequency in 
this study
‡
 
Clinical 
classification 
Reference(s) 
5'UTR to intron 3 Deletion c.-127936_418+7067del p.? 1 H Kataoka et al., 2013 
5'UTR Transition c.-669G>A p.? 1 H Wang et al., 2009 
5'UTR to exon 1 Deletion c.?_-540_76+?del p.? [2] H (n=2) Pfarr et al., 2011 
Exon 1 Deletion c.1-?_76+?del p.? 1 CHD-APAH 
(hereditary) 
Pfarr et al., 2013 
Exons 1-3 Deletion c.1-?_418+?del p.? [2] H, NK Girerd et al., 2010; Kabata et al., 2013 
Exons 1-13 Deletion c.1-?_3117+?del p.? 1 NK Sztrymf et al., 2008 
Exon 1 Nonsense c.16C>T p.Q6* 1 I Kataoka et al., 2013 
Exon 1 Frameshift c.21delG p.W9Gfs*38 1 I Liu et al., 2012 
Exon 1 Nonsense c.27G>A p.W9* 1 I Liu et al., 2012 
Exon 1 Nonsense c.38G>A p.W13* 1 P Chida et al., 2012 
Exon 1 Nonsense c.39G>A p.W13* 1 H Hamid et al., 2010 
Exon 1 Nonsense c.47G>A p.W16* 1 P Kerstjens-Frederikse et al., 2013 
Exon 1 Nonsense c.48G>A p.W16* 4 H, I, NK (n=2) Sztrymf et al., 2008; Pfarr et al., 2011; 
Liu et al., 2012 
Exons 1-6 Deletion c.51_814del p.I18Hfs*25 1 I Machado et al., 2001 
Intron 1 Splice-site c.77-35_86del p.? 1 I Liu et al., 2012 
Exon 2 Deletion c.77-?_247+?del p.? 1 NK Girerd et al., 2010 
Exon 2 Duplication c.77-?_247+?dup p.? 1 H Cogan et al., 2006 
Exons 2-3 Deletion c.77-?_418+?del p.? 1 H Pfarr et al., 2011 
Exons 2-3 Duplication c.77-?_418+?dup p.? 1 I Liu et al., 2012 
Exons 2-7 Duplication c.77-?_967+?dup p.? 1 I Liu et al., 2012 
Exons 2-13 Deletion c.77-?_3117+?del p.? 1 H Cogan et al., 2006 
Exon 2 Nonsense c.88C>T p.Q30* 1 I Liu et al., 2012 
Exon 2 Nonsense c.91G>T p.E31* 1 H Pfarr et al., 2011 
Exon 2 Frameshift c.103delG p.A35Rfs*12 1 I Liu et al., 2012 
Exon 2 Frameshift c.116delC p.P39Rfs*8 1 I Rosenzweig et al., 2008 
Exon 2 Missense c.178T>G p.C60G 1 I Liu et al., 2012 
Exon 2 Missense c.196T>C p.C66R 1 I Wang et al., 2009 
Exon 2 Missense c.197G>A p.C66Y 1 NK Girerd et al., 2010 
Exon 2 Missense c.200A>G p.Y67C 2 I, NK Girerd et al., 2010; Wang et al., 2010 
Exon 2 Frameshift c.200dupA p.Y67* 1 I Kataoka et al., 2013 
Exon 2 Frameshift c.237delT p.V80* 1 H Kataoka et al., 2013 
Exon 2 Frameshift c.240_241insT p.K81* 1 H Johri et al., 2010 
Exon 2 Nonsense c.244C>T p.Q82* 1 H Pfarr et al., 2011 
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Location Mutation 
category 
Nucleotide change
†
 Amino acid change Frequency in 
this study
‡
 
Clinical 
classification 
Reference(s) 
Intron 2 Splice-site c.247+2delC p.G47_Q82del, G63_Q82del 1 H Cogan et al., 2006 
Intron 2 Splice-site c.247+6T>G p.G47_Q82del, G63_Q82del 1 H Cogan et al., 2006 
Intron 2 to exon 3 Deletion c.248-592_413delinsGTAAAGTA p.? 1 I Aimi et al., 2013 
Intron 2 Splice-site c.248-3T>G p.? 1 P Chida et al., 2012 
Exon 3 Deletion c.248-?_418+?del p.? [2] I (n=2) Pfarr et al., 2011; Kabata et al., 2013 
Exon 3 Missense c.251G>T p.C84F 1 I Liu et al., 2012 
Exon 3 Nonsense c.255G>A p.W85* 1 H Kataoka et al., 2013 
Exon 3 Nonsense c.274C>T p.Q92* 1 I Kabata et al., 2013 
Exon 3 Frameshift c.277dupG p.E93Gfs*5 1 I Cogan et al., 2006 
Exon 3 Nonsense c.292G>T p.E98* 1 I Wang et al., 2009 
Exon 3 Nonsense c.320C>G p.S107* 1 NK Sztrymf et al., 2008 
Exon 3 Missense c.338A>G p.Y113C 1 I Liu et al., 2012 
Exon 3 Frameshift c.338dupA p.Y113* 2 H, I Kabata et al., 2013; Kataoka et al., 2013 
Exon 3 Nonsense c.339C>A p.Y113* 1 I Liu et al., 2012 
Exon 3 Missense c.349T>C p.C117R 1 I Liu et al., 2012 
Exon 3 Missense c.353G>A p.C118Y 1 I Pfarr et al., 2011 
Exon 3 Missense c.367T>C p.C123R 1 NK Girerd et al., 2010 
Exon 3 Frameshift c.371dupA p.N124Kfs*6 1 NK Girerd et al., 2010 
Exon 3 Missense c.377A>G p.N126S 5 H, I (n=2), NK 
(n=2) 
Girerd et al., 2010; Pfarr et al., 2011; Liu 
et al., 2012 
Exon 3 Frameshift c.399delT p.P134Lfs*18 1 P Kerstjens-Frederikse et al., 2013 
Exon 3 Frameshift c.407_408delCA p.T136Nfs*10 1 NK Girerd et al., 2010 
Exon 3 Frameshift c.408_412delAACAC p.P138Qfs*7 1 NK Girerd et al., 2010 
Intron 3 Splice-site c.418+3A>T p.? 2 NK (n=2) Sztrymf et al., 2008 
Intron 3 Splice-site c.418+5G>A p.? 1 H Pfarr et al., 2011 
Intron 3 Splice-site c.419-10T>C p.? 1 P Pfarr et al., 2013 
Exons 4-5 Deletion c.419-?_621+?del p.? 1 P Pfarr et al., 2013 
Exons 4-8 Duplication c.419-?_1128+?dup p.? 1 NK Girerd et al., 2010 
Exons 4-13 Deletion c.419-?_3117+?del p.? 1 H Pfarr et al., 2011 
Exon 4 Frameshift c.420_421insG p.P141Afs*6 1 I Arbustini et al., 2008 
Exon 4 Nonsense c.439C>T p.R147* 7 H (n=2), I (n=2), 
NK (n=3) 
Girerd et al., 2010; Wang et al., 2010; 
Pfarr et al., 2011; Liu et al., 2012; 
Momose et al., 2015 
Exon 4 Frameshift c.449dupC p.I151Nfs*30 1 NK Girerd et al., 2010 
Exon 4 Frameshift c.498delT p.A167Pfs*9 2 I (n=2) Kabata et al., 2013; Kataoka et al., 2013 
Exon 4 Nonsense c.507C>A p.C169* 1 I Pfarr et al., 2011 
Exon 4 Nonsense c.516C>G p.Y172* 1 H Cogan et al., 2006 
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Location Mutation 
category 
Nucleotide change
†
 Amino acid change Frequency in 
this study
‡
 
Clinical 
classification 
Reference(s) 
Exon 4 Frameshift c.528delA p.G177Efs*10 2 NK (n=2) Girerd et al., 2010 
Intron 4 Splice-site c.529+2T>C p.? 1 P Chida et al., 2012 
Exon 5 Frameshift c.551_573del p.H184Rfs*8 1 NK Sztrymf et al., 2008 
Exon 5 Frameshift c.608_609delTG p.L203Qfs*16 1 I Wang et al., 2009 
Exon 6 Deletion c.622-?_852+?del p.? 1 NK Girerd et al., 2010 
Exons 6-7 Deletion c.622-?_967+?del p.? 1 I-PAVM Handa et al., 2014 
Exon 6 Nonsense c.631C>T p.R211* 4 H (n=2), NK (n=2) Girerd et al., 2010; Portillo et al., 2010; 
Pfarr et al., 2011 
Exon 6 Nonsense c.637C>T p.R213* 1 H-IPF Raamsteeboers et al., 2014 
Exon 6 Frameshift c.659dupG p.S221Lfs*4 1 H Pfarr et al., 2011 
Exon 6 Missense c.690A>T p.K230N 1 P Hayes et al., 2014 
Exon 6 Missense c.727G>A p.E243K 1 I Wang et al., 2010 
Exon 6 Missense c.727G>C p.E243Q 1 P Chida et al., 2012 
Exon 6 Frameshift c.782_783delTA p.I261Sfs*4 1 NK Girerd et al., 2010 
Exon 6 Frameshift c.796_799delAGAG p.R266Sfs*12 1 H Cogan et al., 2006 
Exon 6 Frameshift c.802dupA p.T268Nfs*30 1 H Wang et al., 2010 
Exon 6 Frameshift c.804delT p.A269Qfs*10 1 H Cogan et al., 2006 
Exon 6 Missense c.830T>C p.L277P 2 I, NK Sztrymf et al., 2008; Liu et al., 2012 
Intron 6 Splice-site c.852+1G>A p.? 1 NK Girerd et al., 2010 
Intron 6 Splice-site c.853-2A>G p.? 1 I Kataoka et al., 2013 
Exon 7 Duplication c.853-?_967+?dup p.? 1 H Aldred et al., 2006 
Exon 7 Frameshift c.872delT p.L291* 1 H Cogan et al., 2006 
Exon 7 Nonsense c.961C>T p.R321* 6 I (n=5), NK Girerd et al., 2010; Wang et al., 2010; 
Pfarr et al., 2011 
Intron 7 Splice-site c.967+5G>C p.? 1 I Liu et al., 2012 
Intron 7 Splice-site c.967+5G>T p.? 1 NK Girerd et al., 2010 
Intron 7 Splice-site c.968-2A>C p.? 1 I Wang et al., 2010 
Exon 8 Deletion c.968-?_1128+?del p.? [2] NK (n=2) Girerd et al., 2010 
Exons 8-9 Deletion c.968-?_1276+?del p.? 1 I Aldred et al., 2006 
Exons 8-10 Duplication c.968-?_1413+?dup p.? 1 I Liu et al., 2012 
Exon 8 Missense c.992A>G p.H331R 1 I Kabata et al., 2013 
Exon 8 Nonsense c.994C>T p.R332* 3 I (n=2), NK Girerd et al., 2010; Portillo et al., 2010; 
Liu et al., 2012 
Exon 8 Missense c.1016T>A p.V339D 2 H, I Kabata et al., 2013; Kataoka et al., 2013 
Exon 8 Frameshift c.1044delT p.I349Lfs*8 1 H Momose et al., 2015 
Exon 8 Frameshift c.1093_1098delinsG p.R365Gfs*5 1 I Liu et al., 2012 
Intron 8 Splice-site c.1128+1G>T p.? 1 H Pfarr et al., 2011 
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Location Mutation 
category 
Nucleotide change
†
 Amino acid change Frequency in 
this study
‡
 
Clinical 
classification 
Reference(s) 
Intron 8 Splice-site c.1129-3C>G p.? 1 I Liu et al., 2012 
Exon 9 Frameshift c.1141dupA p.R381Kfs*18 1 H Hamid et al., 2009 
Exon 9 Nonsense c.1146T>G p.Y382* 1 I Rosenzweig et al., 2008 
Exon 9 Missense c.1151C>T p.A384V 1 I Kabata et al., 2013 
Exon 9 Missense c.1156G>A p.E386K 1 I Rosenzweig et al., 2008 
Exon 9 Missense c.1157A>C p.E386A 1 I Kabata et al., 2013 
Exon 9 Missense c.1157A>G p.E386G 1 I Pfarr et al., 2011 
Exon 9 Missense c.1175T>C p.V392A 2 I (n=2) Wang et al., 2010; Liu et al., 2012 
Exon 9 Nonsense c.1207C>T p.Q403* 1 H Kabata et al., 2013 
Exon 9 Missense c.1228G>A p.G410R 1 H Liu et al., 2012 
Exon 9 Nonsense c.1243G>T p.E415* 1 I Wang et al., 2010 
Exon 9 Missense c.1258T>C p.C420R 1 H Pfarr et al., 2011 
Exon 9 Missense c.1259G>A p.C420Y 2 H, I Pfarr et al., 2011; Liu et al., 2012 
Intron 9 Splice-site c.1276+3A>T p.? 1 NK Girerd et al., 2010 
Introns 9-10 Deletion c.1277-289_1413+4737del p.? 1 I Kataoka et al., 2013 
Intron 9 Splice-site c.1277-9A>G p.? 1 NK Girerd et al., 2010 
Exon 10 Deletion c.1277-?_1413+?del p.? [10] I (n=3), NK (n=7) Sztrymf et al., 2008; Girerd et al., 2010; 
Liu et al., 2012; Kabata et al., 2013 
Exon 10 Duplication c.1277-?_1413+?dup p.? 1 I Liu et al., 2012 
Exon 10 Nonsense c.1296C>G p.Y432* 1 H Pfarr et al., 2011 
Exon 10 Nonsense c.1297C>T p.Q433* 2 I, P Pfarr et al., 2011; Pfarr et al., 2013 
Exon 10 Frameshift c.1313_1316delCAGA p.T438Rfs*35 1 I Pfarr et al., 2011 
Exon 10 Missense c.1346T>G p.M449R 1 H Cogan et al., 2006 
Exon 10 Nonsense c.1348C>T p.Q450* 2 I, NK Girerd et al., 2010; Pfarr et al., 2011 
Exon 10 Frameshift c.1366delinsCA p.E456Qfs*15 1 NK Girerd et al., 2010 
Exon 10 Frameshift c.1371dupA p.Q458Tfs*13 1 I Liu et al., 2012 
Exon 10 Frameshift c.1387_1388insA p.P463Hfs*8 1 I Pfarr et al., 2011 
Exon 10 Frameshift c.1392delA p.A465Pfs*9 1 NK Girerd et al., 2010 
Exon 10 Nonsense c.1397G>A p.W466* 1 I Pfarr et al., 2011 
Exon 10 Frameshift c.1401delA p.E468Kfs*6 1 NK Girerd et al., 2010 
Intron 10 Splice-site c.1413+1G>A p.? 2 I, NK Girerd et al., 2010; Pfarr et al., 2011 
Intron 10 Splice-site c.1413+3A>T p.? 1 NK Pfarr et al., 2011 
Exons 11-12 Deletion c.1414-?_2866+?del p.? [2] I, NK Girerd et al., 2010; Pfarr et al., 2011 
Exons 11-13 Deletion c.1414-?_3117+?del p.? [3] I, NK (n=2) Girerd et al., 2010; Liu et al., 2012 
Exon 11 Nonsense c.1424C>A p.S475* 1 NK Girerd et al., 2010 
Exon 11 Missense c.1460A>T p.D487V 1 H Pfarr et al., 2011 
Exon 11 Missense c.1471C>T p.R491W 13 H (n=5), I (n=3), Girerd et al., 2010; Wang et al., 2010; 
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Location Mutation 
category 
Nucleotide change
†
 Amino acid change Frequency in 
this study
‡
 
Clinical 
classification 
Reference(s) 
NK (n=5) Pfarr et al., 2011; Liu et al., 2012 
Exon 11 Missense c.1472G>A p.R491Q 5 H (n=2), I (n=2), P Portillo et al., 2010; Pfarr et al., 2011; 
Liu et al., 2012; Pfarr et al., 2013 
Exon 11 Nonsense c.1483C>T p.Q495* 1 NK Pfarr et al., 2011 
Exon 11 Nonsense c.1523G>A p.W508* 1 H Pfarr et al., 2011 
Exon 11 Nonsense c.1525G>T p.E509* 1 NK Girerd et al., 2015 
Exon 12 Nonsense c.1750C>T p.R584* 1 I Pfarr et al., 2011 
Exon 12 Nonsense c.1771C>T p.R591* 1 NK Sztrymf et al., 2008 
Exon 12 Frameshift c.1968dupA p.Q657Tfs*18 1 H Kataoka et al., 2013 
Exon 12 Nonsense c.1978G>T p.E660* 1 NK Girerd et al., 2015 
Exon 12 Frameshift c.2009delC p.P670Qfs*30 1 H Kabata et al., 2013 
Exon 12 Frameshift c.2128delC p.L710Sfs*2 2 I (n=2) Kabata et al., 2013; Kataoka et al., 2013 
Exon 12 Frameshift c.2286delC p.N764Ifs*8 1 P Chida et al., 2012 
Exon 12 Frameshift c.2308delC p.R770Gfs*2 2 H, I Rosenzweig et al., 2008; Pfarr et al., 2011 
Exon 12 Frameshift c.2413dupA p.T805Nfs*8 1 I Girerd et al., 2015 
Exon 12 Frameshift c.2446_2447dupGT p.N817Lfs*23 1 I Liu et al., 2012 
Exon 12 Frameshift c.2503_2506delACAA p.T835Pfs*3 2 I (n=2) Liu et al., 2012; Kabata et al., 2013 
Exon 12 Frameshift c.2503dupA p.T835Nfs*8 1 I Kabata et al., 2013 
Exon 12 Frameshift c.2504delC p.T835Kfs*4 1 I Cogan et al., 2006 
Exon 12 Frameshift c.2521_2522dupCA p.R842Ifs*18 1 NK Sztrymf et al., 2008 
Exon 12 Missense c.2588G>A p.S863N 1 H Wang et al., 2009 
Exon 12 Nonsense c.2617C>T p.R873* 7 I (n=5), NK (n=2) Sztrymf et al., 2008; Pfarr et al., 2011; 
Liu et al., 2012; Kabata et al., 2013 
Exon 12 Nonsense c.2626C>T p.Q876* 1 H Pfarr et al., 2011 
Exon 12 Frameshift c.2668delA p.R890Gfs*6 1 P Pfarr et al., 2013 
Exon 12 Nonsense c.2695C>T p.R899* 6 H (n=2), I (n=2), 
NK, P 
Girerd et al., 2010; Wang et al., 2010; 
Pfarr et al., 2011; Liu et al., 2012; 
Kerstjens-Frederikse et al., 2013 
Exon 12 Nonsense c.2752C>T p.Q918* 2 NK (n=2) Girerd et al., 2015 
†
GenBank reference sequence and version number for BMPR2: NM_001204.6; numbering is from +1 as A of the ATG initiation codon 
‡
Total number of independent cases. Frequencies in square brackets denote chromosomal rearrangements for which the breakpoints are unknown and 
may therefore represent distinct mutations 
 
Key to abbreviations: CHD-APAH: congenital heart disease-associated pulmonary arterial hypertension; H: heritable pulmonary arterial hypertension; 
I: idiopathic pulmonary arterial hypertension; IPF: idiopathic pulmonary fibrosis; NK: not known; P: pediatric pulmonary arterial hypertension; PAVM: 
pulmonary arteriovenous malformation 
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Supp. Table S2.  Allelic series of 384 mutations identified across the BMPR2 locus in pulmonary arterial hypertension 
Location Mutation category Nucleotide change
†
 Amino acid change Alternative published nomenclature 
5'UTR to intron 3 Deletion c.-127936_418+7067del p.? c.1-128k_418+7kdel 
5'UTR Indel c.-947_-946delinsAT p.? c.*-944/5GC>AT 
5'UTR Transition c.-669G>A p.? G-669A 
5'UTR to exon 1 Deletion c.?_-540_76+?del p.? c.?_-540_76_?del 
5'UTR to exon 13 Deletion c.?_-540_3117+?del p.?  
Exon 1 Deletion c.1-?_76+?del p.? ?_IVS1 del 
Exons 1-3 Deletion c.1-?_418+?del p.?  
Exons 1-4 Deletion c.1-?_529+?del p.? c.1-?_419+?del 
Exons 1-8 Deletion c.1-?_1128+?del p.? del exon 1-8 
Exons 1-13 Deletion c.1-?_3117+?del p.?  
Exon 1 Frameshift c.9dupC p.S4Lfs*34  
Exon 1 Nonsense c.16C>T p.Q6*  
Exon 1 Frameshift c.16_20delCAGCG p.Q6Afs*30 c.15_19delGCAGC 
Exon 1 Frameshift c.21delG p.W9Gfs*38  
Exon 1 Frameshift c.21_29delinsA p.P8Gfs*27 c.21_29delGCCCTGGCGinsA 
Exon 1 Nonsense c.27G>A p.W9*  
Exon 1 Missense  c.28C>T p.R10W p.T10W 
Exon 1 Nonsense c.38G>A p.W13*  
Exon 1 Nonsense c.39G>A p.W13*  
Exon 1 Frameshift c.44delC p.P15Hfs*32 del44C 
Exon 1 Nonsense c.47G>A p.W16*  
Exon 1 Nonsense c.48G>A p.W16*  
Exons 1-6 Deletion c.51_814del p.I18Hfs*25 51-814 del 
Exon 1 Missense c.71C>A p.A24E  
Intron 1 Splice-site c.76+1G>T p.?  
Intron 1 Splice-site c.76+2T>C p.?  
Intron 1 Splice-site  c.76+5G>A p.?  
Intron 1 Splice-site c.77-35_86del p.? c.77-36_85del 
Intron 1 Splice-site c.77-1G>A p.A26Efs*9  
Exon 2 Deletion c.77-?_247+?del p.A26_Q82del IVS1_IVS2 del 
Exon 2 Duplication c.77-?_247+?dup p.? IVS1_IVS2 dup 
Exons 2-3 Deletion c.77-?_418+?del p.? c.76-?_420+?del 
Del c.77?-c.418? 
Exons 2-3 Duplication c.77-?_418+?dup p.? c.77-?_c.421+?dup 
Exons 2-5 Deletion c.77-?_621+?del p.?  
Exons 2-7 Duplication c.77-?_967+?dup p.? c.77-?_c.967+?dup 
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Location Mutation category Nucleotide change
†
 Amino acid change Alternative published nomenclature 
Exons 2-9 Deletion c.77-?_1276+?del p.?  
Exons 2-13 Deletion c.77-?_3117+?del p.? IVS1_? Del 
Exon 2 Nonsense c.82C>T p.Q28*  
Exon 2 Nonsense c.88C>T p.Q30*  
Exon 2 Nonsense c.91G>T p.E31*  
Exon 2 Missense c.100T>C p.C34R  
Exon 2 Frameshift c.103delG p.A35Rfs*12  
Exon 2 Frameshift c.116delC p.P39Rfs*8  
Exon 2 Nonsense c.120T>G p.Y40*  
Exon 2 Nonsense c.124C>T p.Q42*  
Exon 2 Missense c.125A>G p.Q42R  
Exon 2 Missense c.140G>A p.G47D  
Exon 2 Frameshift c.156_157delTC p.H53* 156-157delTC 
Exon 2 Frameshift c.168delG p.T57Qfs*21 c.166delG 
Exon 2 Missense c.178T>C p.C60R  
Exon 2 Missense c.178T>G p.C60G  
Exon 2 Missense c.179G>A p.C60Y  
Exon 2 Frameshift c.186_187insTACC p.G63Yfs*3 c.186insTACC 
Exon 2 Frameshift  c.189_207delinsGGAGCATAATCAAA p.S64Efs*32 c.189_207delins14 
Exon 2 Deletion c.189_209delTAGCACCTGCTATGGCCTTTG p.S64_W70del c.188-208delGTAGCACCTGCTATGGCCTTT 
c.188-208del21 
c.189-209del21 
Exon 2 Missense c.196T>C p.C66R  
Exon 2 Missense c.196T>G p.C66G  
Exon 2 Missense c.197G>A p.C66Y  
Exon 2 Missense c.200A>G p.Y67C  
Exon 2 Frameshift  c.200dupA p.Y67* c.201insA 
Exon 2 Nonsense c.201T>G p.Y67*  
Exon 2 Missense c.203G>A p.G68D  
Exon 2 Nonsense c.218C>G p.S73*  
Exon 2 Frameshift c.236_238delinsAAAAGGGGACA p.L79Qfs*5  
Exon 2 Frameshift c.237delT p.V80*  
Exon 2 Frameshift c.240_241insT p.K81* c.241insT 
Exon 2 Nonsense c.244C>T p.Q82*  
Exon 2 Missense c.246A>C p.Q82H  
Exon 2 Frameshift c.246dupA p.G83Rfs*15  
Exon 2 Missense  c.247G>A p.G83R  
Intron 2 Splice-site c.247+1G>A p.?  
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Location Mutation category Nucleotide change
†
 Amino acid change Alternative published nomenclature 
Intron 2 Splice-site  c.247+1_247+7delGCAAGTG p.? c.247+1delCAAGTG 
Intron 2 Splice-site c.247+2delC p.G47_Q82del, G63_Q82del IVS2 247+2delC 
Intron 2 Splice-site c.247+6T>G p.G47_Q82del, G63_Q82del IVS2 247+6T>G 
Intron 2 to exon 3 Deletion c.248-592_413delinsGTAAAGTA p.? 756-bp deletion 
Intron 2 Splice-site c.248-5_248delinsAC p.? c.248-5delTATAGGinsAC 
c.-5-248delTATAGGinsAC 
Intron 2 Splice-site c.248-3T>G p.?  
Intron 2 Splice-site c.248-2A>G p.?  
Intron 2 Splice-site c.248-1G>A p.? c.2481-1G>A 
Exon 3 Deletion c.248-?_418+?del p.? IVS2_IVS3 del 
c.?_248-c.418_?del 
c.247-?_420+?del 
Exon 3 Duplication c.248-?_418+?dup p.?  
Exon 3 Missense c.248G>A p.G83E  
Exon 3 Missense c.250T>C p.C84R  
Exon 3 Missense c.250T>G p.C84G  
Exon 3 Missense c.251G>T p.C84F  
Exon 3 Nonsense c.255G>A p.W85*  
Exon 3 Frameshift c.260dupA p.H87Qfs*11 c.261insA 
Exon 3 Missense c.266G>C p.G89A  
Exon 3 Nonsense c.274C>T p.Q92*  
Exon 3 Missense c.276A>C p.Q92H  
Exon 3 Frameshift c.277dupG p.E93Gfs*5 277insG 
Exon 3 Missense c.280T>C p.C94R  
Exon 3 Missense c.280T>G p.C94G  
Exon 3 Missense c.292G>A p.E98K  
Exon 3 Nonsense c.292G>T p.E98*  
Exon 3 Missense c.295T>C p.C99R  
Exon 3 Missense c.296G>A p.C99Y  
Exon 3 Missense c.296G>T p.C99F  
Exon 3 Missense c.304A>G p.T102A  
Exon 3 Missense c.319T>C p.S107P  
Exon 3 Nonsense c.320C>G p.S107*  
Exon 3 Missense c.338A>G p.Y113C  
Exon 3 Frameshift c.338dupA p.Y113* c.399insA 
Exon 3 Nonsense c.339C>A p.Y113*  
Exon 3 Nonsense c.339C>G p.Y113*  
Exon 3 Frameshift c.339_340insAA p.R114Nfs*39  
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Location Mutation category Nucleotide change
†
 Amino acid change Alternative published nomenclature 
Exon 3 Frameshift c.345_346delCT p.F115Lfs*4  
Exon 3 Missense c.349T>C p.C117R  
Exon 3 Missense c.350G>A p.C117Y  
Exon 3 Missense c.350G>C p.C117S  
Exon 3 Missense c.353G>A p.C118Y c.353C>T 
Exon 3 Frameshift c.353delG p.C118Lfs*34  
Exon 3 Missense c.354T>G p.C118W  
Exon 3 Frameshift c.354_355delinsAG p.C118* c.354-355TA>AG 
Exon 3 Frameshift c.355delA p.S119Afs*33  
Exon 3 Frameshift c.359_360delCA p.T120Rfs*4  
Exon 3 Missense c.367T>A p.C123S  
Exon 3 Missense c.367T>C p.C123R  
Exon 3 Missense c.370A>G p.N124D  
Exon 3 Frameshift c.371dupA p.N124Kfs*6 c.371dup 
Exon 3 Missense c.377A>G p.N126S  
Exon 3 Frameshift c.399delT p.P134Lfs*18  
Exon 3 Frameshift c.407_408delCA p.T136Nfs*10 c.407_408del 
Exon 3 Frameshift c.408_412delAACAC p.P138Qfs*7  
Intron 3 Splice-site  c.418+1G>C p.?  
Intron 3 Splice-site c.418+2_418+4delinsGAG p.? c.418+2_418+4TAA>GAG 
Intron 3 Splice-site c.418+3A>T p.?  
Intron 3 Splice-site c.418+5G>A p.?  
Intron 3 Splice-site c.418+5_418+8delGTAA p.C84_S140del c.247+1_+4delGTAA 
Intron 3 Splice-site c.419-10T>C p.?  
Exon 4 Deletion c.419-?_529+?del p.?  
Exons 4-5 Deletion c.419-?_621+?del p.? IVS3_IVS5 del 
del exon 4-5 
Exons 4-7 Deletion c.419-?_967+?del p.?  
Exons 4-8 Duplication c.419-?_1128+?dup p.?  
Exons 4-10 Deletion c.419-?_1413+?del p.?  
Exons 4-13 Deletion c.419-?_3117+?del p.? Del c.419?-c.3017? 
Exon 4 Frameshift c.420_421insG p.P141Afs*6  
Exon 4 Frameshift c.435delT p.F145Lfs*7  
Exon 4 Nonsense c.439C>T p.R147*  
Exon 4 Frameshift c.449dupC p.I151Nfs*30 c.449dup 
Exon 4 Missense c.461C>G p.A154G  
Exon 4 Nonsense c.482T>A p.L161*  
Exon 4 Frameshift c.498delT p.A167Pfs*9 c.497delT 
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Location Mutation category Nucleotide change
†
 Amino acid change Alternative published nomenclature 
Exon 4 Frameshift c.503dupT p.L168Ffs*13 504insT 
c.504_505insT 
Exon 4 Nonsense c.507C>A p.C169*  
Exon 4 Frameshift c.507_510delinsAAA p.C169* c.507-510delCTTTinsAAA 
c.507_510delCTTTinsAAA 
Exon 4 Nonsense c.516C>G p.Y172*  
Exon 4 Frameshift c.528delA p.G177Efs*10  
Intron 4 Splice-site c.529+2T>C p.?  
Exon 5 Deletion c.530-?_621+?del p.?  
Exons 5-7 Deletion c.530-?_967+?del p.? del exon 5/6/7 
Exon 5 Nonsense c.541C>T p.Q181*  
Exon 5 Missense c.545G>A p.G182D  
Exon 5 Frameshift c.551_573delACAGTATGAACATGATGGAGGCA p.H184Rfs*8 c.551_573del 
Exon 5 Missense c.556A>G p.M186V  
Exon 5 Nonsense  c.583G>T p.E195*  
Exon 5 Missense  c.604A>T p.N202Y  
Exon 5 Frameshift c.608_609delTG p.L203Qfs*16 c.608-609delTG 
Exon 5 Frameshift  c.612delA p.K204Nfs*5  
Exon 6 Deletion c.622-?_852+?del p.?  
Exons 6-7 Deletion c.622-?_967+?del p.?  
Exon 6 Nonsense c.631C>T p.R211* c.631G>A 
c.633C>T 
Exon 6 Nonsense c.637C>T p.R213*  
Exon 6 Nonsense c.642T>G p.Y214*  
Exon 6 Frameshift c.659dupG p.S221Lfs*4 c.660insG 
Exon 6 Frameshift c.664_665delinsAAGG p.L222Kfs*9 c.664_665delTTinsAAGG 
Exon 6 Frameshift c.673_679delCGTCCAG p.R225Lfs*3  
Exon 6 Frameshift c.689_690delAA p.K230Sfs*25 c.689-690del 
c.689_690del 
c.689-690delAA 
Exon 6 Missense c.690A>T p.K230N  
Exon 6 Frameshift c.690_691delinsT p.K230Nfs*22 c.690_691delAGinsT 
Exon 6 Missense c.727G>A p.E243K  
Exon 6 Missense c.727G>C p.E243Q  
Exon 6 Nonsense c.727G>T p.E243*  
Exon 6 Frameshift c.775delC p.R259Afs*3  
Exon 6 Frameshift c.782_783delTA p.I261Sfs*4 c.782_783del 
Exon 6 Frameshift c.786dupT p.G263Wfs*3 787insT 
Exon 6 Frameshift c.790delG p.D264Mfs*15  
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Location Mutation category Nucleotide change
†
 Amino acid change Alternative published nomenclature 
Exon 6 Missense c.794A>G p.E265G  
Exon 6 Frameshift c.795_796delinsTT p.E265_L1038delinsD  
Exon 6 Frameshift c.796_799delAGAG p.R266Sfs*12 796-799delAGAG 
Exon 6 Missense c.797G>C p.R266T  
Exon 6 Frameshift c.802dupA p.T268Nfs*30 c.802-803insA 
Exon 6 Frameshift c.804delT p.A269Qfs*10  
Exon 6 Missense c.818T>G p.M273R  
Exon 6 Missense c.830T>C p.L277P  
Intron 6 Splice-site c.852+1G>A p.?  
Intron 6 Splice-site c.852+1G>C p.?  
Intron 6 Splice-site c.853-2A>G p.?  
Intron 6 Splice-site c.853-1G>A p.?  
Intron 6 Splice-site c.853-1G>C p.?  
Exon 7 Duplication c.853-?_967+?dup p.?  
Exon 7 Frameshift c.855delA p.S286Lfs*6  
Exon 7 Nonsense c.860T>A p.L287*  
Exon 7 Nonsense c.872T>G p.L291*  
Exon 7 Frameshift c.872delT p.L291*  
Exon 7 Nonsense c.893G>A p.W298*  
Exon 7 Frameshift c.894_895dupGG p.V299Gfs*2  
Exon 7 Missense c.901T>C p.S301P  
Exon 7 Missense c.908G>A p.R303H  
Exon 7 Nonsense  c.928A>T p.R310*  
Exon 7 Missense c.932G>A p.G311E  
Exon 7 Missense c.937G>C p.A313P  
Exon 7 Missense c.954A>C p.E318D  
Exon 7 Nonsense c.961C>T p.R321*  
Exon 7 Frameshift c.961delC p.R321Efs*14  
Intron 7 Splice-site c.967+2T>C p.?  
Intron 7 Splice-site c.967+4delA p.G285Ifs*12 IVS7 958+3delT 
c.968+3delA 
Intron 7 Splice-site c.967+5G>C p.?  
Intron 7 Splice-site c.967+5G>T p.?  
Intron 7 Splice-site c.968-5A>G p.?  
Intron 7 Splice-site c.968-3C>G p.?  
Intron 7 Splice-site c.968-2A>C p.? c.965-2A>C 
Intron 7 Splice-site c.968-1G>T p.?  
Exon 8 Deletion c.968-?_1128+?del p.? c.968-?_1129+?del 
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Location Mutation category Nucleotide change
†
 Amino acid change Alternative published nomenclature 
Exons 8-9 Deletion c.968-?_1276+?del p.? c.967-?_1275+?del 
Exons 8-10 Duplication c.968-?_1413+?dup p.? c.968-?_c.1413+?dup 
Exon 8 Frameshift c.969dupT p.H324Sfs*3 c.967_968insA 
c.968_969insT 
Exon 8 Frameshift c.980delC p.P327Lfs*8  
Exon 8 Missense c.992A>G p.H331R  
Exon 8 Nonsense c.994C>T p.R332*  
Exon 8 Nonsense c.1001T>G p.L334*  
Exon 8 Frameshift c.1011_1015delAAATG p.R337Sfs*6  
Exon 8 Missense c.1016T>A p.V339D  
Exon 8 Missense  c.1019T>C p.L340P  
Exon 8 Missense c.1039T>C p.C347R  
Exon 8 Missense c.1040G>A p.C347Y 1042G>A 
Exon 8 Missense c.1042G>A p.V348I  
Exon 8 Frameshift c.1044delT p.I349Lfs*8  
Exon 8 Frameshift c.1060delC p.L354Cfs*3  
Exon 8 Missense c.1066A>T p.M356L  
Exon 8 Frameshift c.1076delC p.T359Mfs*16  
Exon 8 Frameshift c.1093_1098delinsG p.R365Gfs*5  
Exon 8 Frameshift c.1097delC p.P366Qfs*9 c.1095delC 
Exon 8 Frameshift c.1101_1105delGGAGG p.E368Rfs*2 c.1099_1103del 
c.1099-1103delGGGGA 
c.1099_1103delGGGGA 
Exon 8 Frameshift c.1113dupT p.A372Cfs*27 c.1113delT 
Exon 8 Missense c.1117G>C p.A373P  
Exon 8 Frameshift c.1120delA p.I374*  
Exon 8 Nonsense c.1126G>T p.E376*  
Intron 8 Splice-site c.1128+1G>A p.?  
Intron 8 Splice-site c.1128+1G>T p.? IVS8 +1G>T 
IVS8 1128+1G>T 
Intron 8 Splice-site c.1129-3C>G p.? IVS8 1129-3C>G 
Exon 9 Frameshift c.1129-1_1129dupGG p.V377Gfs*13  
Exon 9 Frameshift c.1141dupA p.R381Kfs*18 c.1141_1142insA 
Exon 9 Nonsense c.1146T>G p.Y382*  
Exon 9 Missense c.1151C>T p.A384V  
Exon 9 Missense c.1156G>A p.E386K  
Exon 9 Missense c.1156G>C p.E386Q  
Exon 9 Missense c.1157A>C p.E386A  
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Location Mutation category Nucleotide change
†
 Amino acid change Alternative published nomenclature 
Exon 9 Missense c.1157A>G p.E386G  
Exon 9 Missense c.1157A>T p.E386V  
Exon 9 Missense  c.1171G>A p.A391T  
Exon 9 Missense c.1175T>C p.V392A  
Exon 9 Frameshift c.1191_1192delTG p.C397* 1191/1192delTG 
c.1189-1190delTG 
Exon 9 Nonsense c.1196C>G p.S399*  
Exon 9 Missense c.1202T>C p.L401S  
Exon 9 Nonsense c.1207C>T p.Q403* C1207T 
Exon 9 Frameshift c.1214delA p.D405Afs*7  
Exon 9 Missense c.1220A>C p.Y407S  
Exon 9 Nonsense c.1221T>G p.Y407*  
Exon 9 Missense c.1228G>A p.G410R  
Exon 9 Nonsense c.1241G>A p.W414*  
Exon 9 Nonsense c.1243G>T p.E415*  
Exon 9 Frameshift c.1245_1246dupGA p.I416Rfs*4 c.1246dupGA 
1247/8insGA 
Exon 9 Frameshift c.1246_1247insG p.I416Sfs*32 c.1246dupG 
Exon 9 Frameshift c.1247_1250delinsGA p.I416Rfs*31 c.1246_1247dupGA; 1250_1253delTTAT 
Exon 9 Frameshift c.1248delA p.F417Lfs*2  
Exon 9 Frameshift c.1250_1253delTTAT p.F417* c.1248-1251delATTT 
Exon 9 Missense c.1257A>T p.R419S  
Exon 9 Missense c.1258T>C p.C420R  
Exon 9 Missense c.1259G>A p.C420Y  
Exon 9 Frameshift c.1268dupT p.F424Lfs*24  
Exon 9 Frameshift c.1271_1276delinsCGGAGA p.F424_G426delinsSER c.1271delTCCCAGinsCGGAGA 
Exon 9 Frameshift c.1274dupC p.G426Rfs*22 c.1272insC 
c.1274dup 
Exon 9 Missense c.1276G>C p.G426R  
Intron 9 Splice-site c.1276+1G>A p.?  
Intron 9 Splice-site c.1276+3A>G p.?  
Intron 9 Splice-site c.1276+3A>T p.?  
Intron 9 Splice-site c.1276+4A>G p.?  
Introns 9-10 Deletion c.1277-289_1413+4737del p.? c.1277-291_1413+4735del 
Intron 9 Splice-site c.1277-9A>C p.?  
Intron 9 Splice-site c.1277-9A>G p.?  
Intron 9 Splice-site c.1277-8A>G p.?  
Exon 10 Deletion c.1277-?_1413+?del p.? c.1277-?_c.1413+?del 
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Exon 10 Duplication c.1277-?_1413+?dup p.? IVS9_IVS10 dup 
c.1277-?.1413+?dup 
c.1277-?_c.1413+?dup 
Exon 10 Frameshift c.1279delG p.E427Nfs*47  
Exon 10 Frameshift c.1285_1286insGGATT p.V429Gfs*47  
Exon 10 Frameshift c.1293_1300delGTACCAGA p.E431Dfs*14  
Exon 10 Nonsense c.1296C>G p.Y432*  
Exon 10 Nonsense c.1297C>T p.Q433*  
Exon 10 Frameshift c.1313_1316delCAGA p.T438Rfs*35 c.1313-1316delCAGA 
Exon 10 Missense c.1346T>G p.M449R  
Exon 10 Nonsense c.1348C>T p.Q450*  
Exon 10 Frameshift c.1366delinsCA p.E456Qfs*15  
Exon 10 Frameshift c.1371delA p.K457Nfs*17  
Exon 10 Frameshift c.1371dupA p.Q458Tfs*13 c.1371dup 
Exon 10  Frameshift c.1376_1377delGA p.R459Tfs*11 c.1375_1376delAG 
Exon 10 Frameshift c.1387_1388insA p.P463Hfs*8 c.1388insA 
Exon 10 Frameshift c.1389dupA p.E464Rfs*7 c.1388-1389insA 
c.1388_1389insA 
Exon 10 Frameshift c.1392delA p.A465Pfs*9  
Exon 10 Nonsense c.1397G>A p.W466*  
Exon 10 Nonsense c.1398G>A p.W466*  
Exon 10 Frameshift c.1401delA p.E468Kfs*6 c.1399delA 
c.1401del 
Exon 10 Nonsense c.1402G>T p.E468*  
Intron 10 Splice-site c.1413+1G>A p.?  
Intron 10 Splice-site c.1413+3A>T p.? IVS10 +3A>T 
Intron 10 Splice-site c.1414-2A>T p.?  
Exons 11-12 Deletion c.1414-?_2866+?del p.? Del c.1414-?_2866+? 
Exons 11-13 Deletion c.1414-?_3117+?del p.? c.1414-?_3114+?del 
c.1414-?_c.3117+?del 
Exon 11 Nonsense c.1424C>A p.S475*  
Exon 11 Frameshift c.1426_1450delCTCAAGGAGACAATCGAAGACTGTT p.L476Gfs*22 c.1426_1450del 
Exon 11 Frameshift c.1427delT p.L476Pfs*30 c.1426delT 
Exon 11 Nonsense c.1441G>T p.E481*  
Exon 11 Missense c.1447T>C p.C483R  
Exon 11 Nonsense c.1451G>A p.W484*  
Exon 11 Missense c.1453G>A p.D485N  
Exon 11 Missense c.1454A>G p.D485G  
Exon 11 Nonsense c.1456C>T p.Q486*  
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Exon 11 Missense c.1460A>T p.D487V  
Exon 11 Missense c.1469C>T p.A490V  
Exon 11 Missense c.1471C>T p.R491W  
Exon 11 Missense c.1472G>A p.R491Q  
Exon 11 Frameshift c.1477dupA p.T493Nfs*6  
Exon 11 Nonsense c.1483C>T p.Q495*  
Exon 11 Missense c.1486T>C p.C496R  
Exon 11 Missense c.1487G>A p.C496Y  
Exon 11 Missense c.1509A>C p.E503D  
Exon 11 Missense c.1516A>G p.M506V  
Exon 11 Nonsense c.1523G>A p.W508*  
Exon 11 Nonsense c.1525G>T p.E509*  
Exon 11 Missense c.1535A>C p.K512T  
Exon 11 Missense c.1557T>A p.N519K  
Exon 11 Frameshift c.1585delC p.R529Afs*35  
Intron 11 Splice-site c.1587-7_1587-4delCTTT p.?  
Exon 12 Missense c.1598A>G p.H533R  
Exon 12 Nonsense c.1629T>G p.Y543*  
Exon 12 Missense c.1687G>A p.V563M  
Exon 12 Nonsense c.1750C>T p.R584*  
Exon 12 Missense c.1766A>G p.Y589C  
Exon 12 Nonsense c.1771C>T p.R591*  
Exon 12 Nonsense c.1789C>T p.R597*  
Exon 12 Frameshift c.1954_1955dupAC p.V654Lfs*6 c.1954_1955dup 
c.1954dupA 
c.1956insAC 
c.1956_1957insAC 
Exon 12 Frameshift c.1968dupA p.Q657Tfs*18 c.1969insA 
c.1969_1970insA 
Exon 12 Nonsense c.1969C>T p.Q657*  
Exon 12 Nonsense c.1978G>T p.E660*  
Exon 12 Nonsense c.1981G>T p.E661*  
Exon 12 Frameshift c.2009delC p.P670Qfs*30  
Exon 12 Nonsense c.2124C>G p.Y708*  
Exon 12 Frameshift c.2128delC p.L710Sfs*2  
Exon 12 Frameshift c.2286delC p.N764Ifs*8 c.2289delC 
Exon 12  Frameshift c.2291dupA p.N764Kfs*49 2292insA 
Exon 12 Missense c.2296A>G p.T766A  
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Exon 12 Frameshift c.2297delC p.T766Kfs*6 delC2705 
Exon 12 Frameshift c.2303_2309delAGCCCCG p.E768Gfs*2  
Exon 12 Frameshift c.2308delC p.R770Gfs*2 c.2305delC 
Exon 12 Frameshift c.2386delG p.A796Qfs*7  
Exon 12 Frameshift c.2407_2408insTG p.T803Mfs*5 2408insTG 
c.2408_2409insTG 
Exon 12 Frameshift c.2410_2413delGTCA p.V804Pfs*2 c.2410-2413delGTCA 
Exon 12 Frameshift c.2413dupA p.T805Nfs*8  
Exon 12 Frameshift c.2442_2443delCA p.H814Qfs*3 c.2441-2442delAC 
Exon 12 Frameshift c.2446_2447dupGT p.N817Lfs*23 c.2446_2447dup 
Exon 12 Frameshift c.2484delG p.T829Qfs*10  
Exon 12 Frameshift c.2503dupA p.T835Nfs*8 c.2504insA 
Exon 12 Frameshift c.2503_2506delACAA p.T835Pfs*3 c.2500delCAAA 
c.2503_2506del 
Exon 12 Frameshift c.2504delC p.T835Kfs*4  
Exon 12 Frameshift c.2506_2522delACCAACATAGTGACACA p.T836* c.2506_2522del17 
Exon 12 Frameshift c.2521_2522dupCA p.R842Ifs*18  
Exon 12 Frameshift c.2527delG p.A843Pfs*16  
Exon 12 Nonsense c.2533G>T p.E845*  
Exon 12 Frameshift c.2580delT p.N861Ifs*11 c.2579delT 
2579-2580 delT 
Exon 12 Missense c.2588G>A p.S863N  
Exon 12 Frameshift c.2609delT p.L870Yfs*2  
Exon 12 Nonsense c.2617C>T p.R873*  
Exon 12 Missense c.2618G>A p.R873Q  
Exon 12 Nonsense c.2620G>T p.E874*  
Exon 12 Nonsense c.2626C>T p.Q876*  
Exon 12 Frameshift c.2668delA p.R890Gfs*6  
Exon 12 Nonsense c.2695C>T p.R899*  
Exon 12 Missense c.2696G>C p.R899P  
Exon 12 Missense c.2708A>G p.N903S  
Exon 12 Nonsense c.2730T>A p.C910*  
Exon 12 Nonsense c.2737C>T p.Q913*  
Exon 12 Nonsense c.2752C>T p.Q918*  
Exon 12 Nonsense c.2789C>G p.S930*  
Exon 13 Missense  c.2945A>G p.K982R  
†
GenBank reference sequence and version number for BMPR2: NM_001204.6; numbering is calculated from +1 as A of the ATG initiation codon. All 
nomenclature has been updated according to the most recent HGVS guidelines: http://www.hgvs.org/mutnomen. 
Machado et al., Human Mutation  17 
Supp. References 
Aimi Y, Hirayama T, Kataoka M, Momose Y, Nishimaki S, Matsushita K, Yoshino H, Satoh T, Gamou S. 2013. A novel break point of the BMPR2 gene 
exonic deletion in a patient with pulmonary arterial hypertension. J Hum Genet 58:815-818. 
Aldred MA, Vijayakrishnan J, James V, Soubrier F, Gomez-Sanchez MA, Martensson G, Galie N, Manes A, Corris P, Simonneau G, Humbert M, 
Morrell NW, et al. 2006. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial 
hypertension. Hum Mutat 27:212-213. 
Arbustini E, Marziliano N, Porcu E, Pasotti M, Grasso M, Tagliani M, Disabella E, Diegoli M, Pilotto A, Ghio S, Campana C, D'Armini A, Vigano M. 
2008. Gene symbol: BMPR2. Disease: Pulmonary hypertension, primary. Hum Genet 123:112-113. 
Chida A, Shintani M, Yagi H, Fujiwara M, Kojima Y, Sato H, Imamura S, Yokozawa M, Onodera N, Horigome H, Kobayashi T, Hatai Y, et al. 2012. 
Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J Cardiol 110:586-593. 
Cogan JD, Pauciulo MW, Batchman AP, Prince MA, Robbins IM, Hedges LK, Stanton KC, Wheeler LA, Phillips JA, 3rd, Loyd JE, Nichols WC. 2006. 
High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 174:590-598. 
Girerd B, Montani D, Eyries M, Yaici A, Sztrymf B, Coulet F, Sitbon O, Simonneau G, Soubrier F, Humbert M. 2010. Absence of influence of gender 
and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 11:73. 
Girerd B, Coulet F, Jais X, Eyries M, Van Der Bruggen C, De Man F, Houweling A, Dorfmuller P, Savale L, Sitbon O, Vonk-Noordegraaf A, Soubrier 
F, et al. 2015. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone 
morphogenetic protein receptor type 2. Chest 147:1385-1394. 
Hamid R, Cogan JD, Hedges LK, Austin E, Phillips JA, 3rd, Newman JH, Loyd JE. 2009. Penetrance of pulmonary arterial hypertension is modulated by 
the expression of normal BMPR2 allele. Hum Mutat 30:649-654. 
Hamid R, Hedges LK, Austin E, Phillips JA, 3rd, Loyd JE, Cogan JD. 2010. Transcripts from a novel BMPR2 termination mutation escape nonsense 
mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension. Clin Genet 77:280-286. 
Handa T, Okano Y, Nakanishi N, Morisaki T, Morisaki H, Mishima M. 2014. BMPR2 gene mutation in pulmonary arteriovenous malformation and 
pulmonary hypertension: a case report. Respir Investig 52:195-198. 
Hayes D, Jr., Ramanathan C, Kopp BT. 2014. The BMPR2 missense mutation p.K230N and pulmonary arterial hypertension. Pediatr Pulmonol 49:E5-6. 
Johri S, Dunnington GH, Vnencak-Jones CL. 2010. A novel BMPR2 mutation associated with pulmonary arterial hypertension in an octogenarian. Lung 
188:349-352. 
Kabata H, Satoh T, Kataoka M, Tamura Y, Ono T, Yamamoto M, Huqun, Hagiwara K, Fukuda K, Betsuyaku T, Asano K. 2013. Bone morphogenetic 
protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension. 
Respirology 18:1076-1082. 
Machado et al., Human Mutation  18 
Kataoka M, Aimi Y, Yanagisawa R, Ono M, Oka A, Fukuda K, Yoshino H, Satoh T, Gamou S. 2013. Alu-mediated nonallelic homologous and 
nonhomologous recombination in the BMPR2 gene in heritable pulmonary arterial hypertension. Genet Med 15:941-947. 
Kerstjens-Frederikse WS, Bongers EM, Roofthooft MT, Leter EM, Douwes JM, Van Dijk A, Vonk-Noordegraaf A, Dijk-Bos KK, Hoefsloot LH, 
Hoendermis ES, Gille JJ, Sikkema-Raddatz B, et al. 2013. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary 
arterial hypertension. J Med Genet 50:500-506. 
Liu D, Liu QQ, Eyries M, Wu WH, Yuan P, Zhang R, Soubrier F, Jing ZC. 2012. Molecular genetics and clinical features of Chinese idiopathic and 
heritable pulmonary arterial hypertension patients. Eur Respir J 39:597-603. 
Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA, 3rd, Newman J, Williams D, Galie N, Manes A, McNeil K, et 
al. 2001. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68:92-102. 
Momose Y, Aimi Y, Hirayama T, Kataoka M, Ono M, Yoshino H, Satoh T, Gamou S. 2015. De novo mutations in the BMPR2 gene in patients with 
heritable pulmonary arterial hypertension. Ann Hum Genet 79:85-91. 
Pfarr N, Szamalek-Hoegel J, Fischer C, Hinderhofer K, Nagel C, Ehlken N, Tiede H, Olschewski H, Reichenberger F, Ghofrani AH, Seeger W, Grunig 
E. 2011. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res 12:99. 
Pfarr N, Fischer C, Ehlken N, Becker-Grunig T, Lopez-Gonzalez V, Gorenflo M, Hager A, Hinderhofer K, Miera O, Nagel C, Schranz D, Grunig E. 
2013. Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial 
hypertension. Respir Res 14:3. 
Portillo K, Santos S, Madrigal I, Blanco I, Pare C, Borderias L, Peinado VI, Roca J, Mila M, Barbera JA. 2010. Study of the BMPR2 gene in patients 
with pulmonary arterial hypertension. Arch Bronconeumol 46:129-134. 
Raamsteeboers AJ, Bogaard HJ, Vonk Noordegraaf A. 2014. Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 
mutation positive patient. Eur Respir Rev 23:147-149. 
Rosenzweig EB, Morse JH, Knowles JA, Chada KK, Khan AM, Roberts KE, McElroy JJ, Juskiw NK, Mallory NC, Rich S, Diamond B, Barst RJ. 2008. 
Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart 
Lung Transplant 27:668-674. 
Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M. 2008. Clinical outcomes of 
pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 177:1377-1383. 
Wang H, Li W, Zhang W, Sun K, Song X, Gao S, Zhang C, Hui R, Hu H. 2009. Novel promoter and exon mutations of the BMPR2 gene in Chinese 
patients with pulmonary arterial hypertension. Eur J Hum Genet 17:1063-1069. 
Wang H, Cui QQ, Sun K, Song L, Zou YB, Wang XJ, Jia L, Liu X, Gao S, Zhang CN, Hui RT. 2010. Identities and frequencies of BMPR2 mutations in 
Chinese patients with idiopathic pulmonary arterial hypertension. Clin Genet 77:189-192. 
